Next Article in Journal
Landscape Analysis of Public Health Jobs in India to Develop an Evidence-Based Public Health Curriculum
Next Article in Special Issue
Association between Perceived Health-Related Quality of Life and Depression with Frailty in the FRASNET Study
Previous Article in Journal
Benefits of a Wearable Activity Tracker with Safety Features for Older Adults: An Intervention Study
Previous Article in Special Issue
Social Determinants of the Non-Utilization of the Supplementary Feeding Program (PACAM) Aimed at Older Adults’ Nutritional Support
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Current Evidence on the Association of Micronutrient Malnutrition with Mild Cognitive Impairment, Frailty, and Cognitive Frailty among Older Adults: A Scoping Review

1
Center for Healthy Aging and Wellness, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, Kuala Lumpur 50300, Malaysia
2
Genome Health Foundation, North Brighton, SA 5048, Australia
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2022, 19(23), 15722; https://doi.org/10.3390/ijerph192315722
Submission received: 19 October 2022 / Revised: 10 November 2022 / Accepted: 13 November 2022 / Published: 25 November 2022
(This article belongs to the Special Issue Frailty in the Elderly: Issues and Challenges)

Abstract

:
Micronutrient malnutrition is thought to play an important role in the cause of cognitive impairment and physical frailty. The purpose of this scoping review was to map current evidence on the association between micronutrient deficiency in blood and mild cognitive impairment, frailty, and cognitive frailty among older adults. The scoping review was conducted based on the 2005 methodological framework by Arksey and O’Malley. The search strategy for potential literature on micronutrient concentration in blood and cognitive frailty was retrieved based on the keywords using electronic databases (PubMed, Cochrane Library, Google Scholar, Ovid, and Science Direct) from January 2010 to December 2021. Gray literature was also included in the searches. A total of 4310 articles were retrieved and 43 articles were incorporated in the review. Findings revealed a trend of significant association between low levels of B vitamins (folate and vitamin B12), vitamin D, vitamin A, vitamin E, omega 3 fatty acid, and albumin, and high homocysteine levels in blood with an increased risk of mild cognitive impairment among older adults. The results also indicated that low vitamin D levels, albumin, and antioxidants (lutein and zeaxanthin) in blood were significantly associated with frailty among older adults, while β-cryptoxanthin and zeaxanthin in blood were inversely associated with the risk of cognitive frailty. Vitamin D and antioxidants seemed to be targeted nutrients for the prevention of cognitive frailty. In conclusion, a wide range of micronutrient deficiency was associated with either mild cognitive impairment or frailty; however, little evidence exists on the dual impairment, i.e., cognitive frailty. This scoping review can serve as preliminary evidence for the association between micronutrient deficiency in blood and mild cognitive impairment, frailty, and cognitive frailty among older adults and prove the relevancy of the topic for future systematic reviews.

1. Introduction

Cognitive frailty (CF) is a predementia syndrome characterized by the simultaneous presence of both frailty and cognitive impairment [1]. It has been discovered to be associated with disability and an increase in mortality rates [2]. Frailty is defined by five phenotype models: unintentional weight loss, fatigue, weakness, decreased gait speed, and physical inactivity [3]. Frailty is associated with the increased risk of falls, functional disability, hospitalization, poor quality of life, and death [3]. Mild cognitive impairment (MCI) is defined as a syndrome where cognitive decline is greater than is expected for an individual’s age and education level but does not notably interfere with daily life activities [4]. MCI is associated with an increased risk of dementia [4]. The prevalence rate of cognitive frailty is between 1.0% and 12.0% among community-dwelling older adults [4,5]. Frailty affects 12% of the community dwellers aged ≥50 years [6], while cognitive impairment is present at a range of 5.1% to 41% [7,8]. Furthermore, a recent systematic review concluded that physical frailty is associated cross-sectionally and prospectively with a worse cognitive trajectory among those with MCI [9].
Cognitive frailty can be influenced by several risk factors, including impaired cardiovascular function, unhealthy lifestyle habits (smoking and inadequate physical activity), poor nutritional status, and adverse psychosocial experiences [10]. Increased age, vitamin D deficiency, co-existence of depression, frailty, and declined functional mobility and processing speed are among the predictors of CF [8,11]. Furthermore, for frailty, the risk factors are increasing age, body fat, lower skeletal muscle, malnutrition, low calcium intake, abdominal obesity, and poor physical function [12,13]. On the other hand, the risk factors for mild cognitive impairment are advanced age, low education level, living alone, low level of life satisfaction, less engagement in mental activities, low intake of fruits and vegetables, and not practicing calorie restriction [8,14,15]. Adequate-to-high protein [16] and at least 16 micronutrients, i.e., beta-alanine, calcium, creatinine, fluorides, leucine, magnesium, omega-3 fatty acids, potassium, vitamin B6, vitamin B9 (folate), vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K2, and zinc, have been reported to be beneficial in improving musculoskeletal health and/or cognitive function in older people [17]. However, quite often, nutritional deficiencies have not been given equal emphasis in the effort to improve health among the adult population [18].
Nutritional deficits in older adults can impair or affect their level of physical and cognitive functioning [19]. Specific nutrient deficiencies such as some B vitamins, minerals, lipids, and antioxidants that occur during the life cycle can intensify brain physiological mechanisms that may increase the vulnerability to DNA damage in brain cells, which contributes to cognitive decline [20]. Furthermore, micronutrient malnutrition such as vitamin D deficiency and low plasma levels of essential amino acids is also the cause of frailty [21,22]. Insufficiency of vitamin D [23], and low levels of n−3PUFA, in particular, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) [24], influence not only physical and musculoskeletal function but also cognitive functioning in older subjects.
Mild cognitive impairment, as well as physical and cognitive frailty are potentially reversible if detected early and can be subjected to appropriate intervention strategies at the primary stage; thus, older adults may be able to return to normal cognition [2,8]. Comprehensive multimodality interventions comprising of nutritional, physical, and cognitive intervention have been reported to be superior in reversing frailty in older adults [25]. A multidomain intervention which includes four intervention components such as diet, exercise, cognitive training, and vascular risk monitoring could improve or maintain the cognitive functioning of these individuals [26].
Although micronutrient deficiency has been reported to influence cognitive impairment, frailty, and cognitive frailty, to our knowledge, there is no comprehensive scoping review available regarding the association of micronutrient deficiency in blood with mild cognitive impairment, frailty, and cognitive frailty among older adults. For example, previous work has only highlighted the association between vitamins with MCI and AD [27]. Therefore, in the present study, we aimed to carry out a scoping review to map current evidence not only on vitamins but also the association of micronutrient deficiency in blood with a broader scope of cognitive disorders, namely, cognitive impairment, frailty, and cognitive frailty among older adults. This review may act as a precursor for a full systematic review and to improve the understanding of the association between micronutrient deficiency in blood and MCI, frailty, and CF, leading to personalized rehabilitation for reversing CF. Unlike systematic reviews and narrative reviews, scoping reviews evaluate the existing literature, summarize the findings, provide information on knowledge gaps, and are the first step before conducting a systematic review [28,29].

2. Materials and Methods

This study adopted the Arksey and O’Malley’s (2005) framework for scoping review and as the foundation of the methodology [28]. According to the framework, there are five different stages which include stage 1: identifying the research question; stage 2: identifying relevant studies; stage 3: selecting studies; stage 4: charting the data; and stage 5: collating, summarizing, and reporting the results.

2.1. Stage 1: Identifying the Research Question

Describing the definition of a relevant research question is a crucial step to define and refine the chosen research strategy. Based on the statement by Arksey and O’Malley, we have identified one research question that was used to guide our systematic search strategy and reporting of results [28]. The research question that we focused on was: is there any association between micronutrient concentration in blood with mild cognitive impairment, frailty, and cognitive frailty among older adults?

2.2. Stage 2: Identifying Relevant Studies

The identification of the relevant literature was performed using different resources. These included various electronic databases (PubMed, Cochrane Library, Google Scholar, Ovid, and Science Direct). Gray literature (i.e., unpublished or difficult-to-locate materials) searches of the local journal, Malaysian Nutrition Research Bibliography (2011–2014 and 2015–2017), and online local databases were also conducted to maximize the search activities.
Table 1 lists the initial keywords and search terms generated. The search terms from the keywords, subject headings, and synonyms such as blood micronutrient profiles, albumin, homocysteine, amino acids, minerals, vitamins, antioxidants, cognitive frailty, mild cognitive impairments, physical frailty, frailty syndrome, debility, older adults, aging population, older population, aging, and elderly were generated by the research team to capture any potential resources from the database. Boolean operators (AND, OR, NOT) were employed to combine the search terms using the related keywords. Table 2 shows the search strings generated.

2.3. Stage 3: Selecting Studies

Our review inclusion criteria were as follows: (1) articles written in the English language; (2) publications for the period between January 2010 and December 2021; (3) articles describing studies on the association of micronutrient profiles in blood and cognitive frailty among older adults; and (4) the definition of the older adult population by age according to the country of origin. A 10-year time frame was selected because it was expected that this period would cover the most significant results on the recent literature for this topic [30]. The following were the exclusion criteria: (1) articles concerning individuals of other age ranges instead of elderly subjects; (2) animal studies; and (3) review articles. The studies were chosen and recorded in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flow diagram for the scoping review process [31]. The selection of the articles was performed in two stages. In the first stage, two researchers independently screened the titles and abstracts of all resources based on the inclusion criteria and search terms. Irrelevant abstracts were removed, and the researchers then retrieved full articles based on the abstracts that were chosen. The full articles were then independently screened by two researchers to identify items related to the objectives of the review in the second stage. Articles were removed if they were unrelated to the objectives of the review. The search results were managed using the Mendeley Desktop software.

2.4. Stage 4: Charting the Data

The data charting process generated a summary of the articles that corresponded to the study’s objectives and research question. Data were extracted from the selected articles by the researchers and included in the charting table. These data included information of the studies such as the author(s), year of publication, country origin, study design, participants’ characteristics, blood micronutrient profiles results and methods of measurement, and findings.

2.5. Stage 5: Collating, Summarizing, and Reporting the Results

The collating process of this scoping review followed the PRISMA flow diagram to ensure the review search results could be reported accurately [31]. Tables were created to summarize the findings of the selected articles and analyzed to elucidate the association of blood micronutrient profiles and cognitive frailty among older adults. The results of the extracted data were analyzed using descriptive statistics to provide a summary of the studies based on the number and types of studies and their research scopes.

3. Results

3.1. Characteristics and Participants of the Selected Studies

The identification step retrieved 4310 articles using the search engines mentioned and the gray literature. The duplicates were then removed, and the remaining 3591 articles were examined for relevant abstracts. This procedure resulted in 162 articles that were reviewed for inclusion eligibility. Finally, 43 articles that met the inclusion criteria were identified (Figure 1) with 31 studies that were conducted among older adults with mild cognitive impairments, and 11 studies on older adults with frailty (Table 3). There was also only one study on cognitive frailty as this concept was newly defined in 2013, and thus, related research was still limited. The majority of the studies were cross-sectional studies (n = 28), and the remaining were prospective (n = 10), retrospective (n = 2), and case-control (n = 3) studies. Cohort (prospective or retrospective study design) and case-control studies have specific advantages by offering a temporal dimension to measure disease incidents and their association with an exposure. With respect to the cross-sectional studies, it involved examining data on diseases and exposure at one particular time point; therefore, it could not assess the cause and effect relationship [32]. Studies were conducted in more than 23 countries, i.e., Italy, Chile, China, France, Switzerland, the United Kingdom, Sweden, Korea, the United States, Germany, Finland, Australia, Brazil, Japan, Malaysia, Thailand, India, Taiwan, Turkey, Mexico, Australia, Spain, and Sweden. The samples’ sizes ranged from 68 to 6257 participants. The participants’ ages in these studies ranged depending on the different methodology conducted.

3.2. Association of Vitamin D with Mild Cognitive Impairment, Frailty, and Cognitive Frailty

There were twenty-five studies that investigated the association between vitamin D with mild cognitive impairment and frailty (Table 3). From the identified studies, nine cross-sectional studies reported that lower vitamin D levels were significantly associated with mild cognitive impairment [33,34,35,36,37,38,39,40,41], while findings from eight cross-sectional studies [21,42,43,44,45,46,47,48] reported an association with frailty. Besides that, four prospective studies found that lower vitamin D levels were associated with mild cognitive impairment [49,50,51,52]; however, one prospective study conducted by Graf et al. (2014) found that vitamin D was not associated with mild cognitive impairment [53]. In regard to frailty, two prospective studies discovered that low levels of vitamin D were significantly associated with frailty [54,55], and one prospective study by Buta et al. (2016) revealed that low levels of vitamin D were not significantly associated with frailty incidence after the presence of cardiometabolic diseases was accounted for [56]. There were several techniques for measuring vitamin D identified in this review, including the immunoassay method [34,35,36,37,53] and the mass spectrometry method [47,51,52].
Table 3. Summary of studies evaluating the association between vitamin D with mild cognitive impairment, frailty, and cognitive frailty involved in the elderly.
Table 3. Summary of studies evaluating the association between vitamin D with mild cognitive impairment, frailty, and cognitive frailty involved in the elderly.
Author, Year, CountryStudy DesignParticipant CharacteristicsMicronutrients in Blood Profiles’ Outcomes and Methods of MeasurementFindings
Chei et al., 2014 [33]
China
Cross-sectional studySubjects: 2004 older adults from the Chinese Longitudinal Healthy Longevity Survey (936 males and 1068 females)
Age: 60 years old and older
Fasting venous blood was collected and then plasma was stored at −80 °C until analysis. Plasma 25(OH)D3 levels were measured using an
enzyme-linked
immunosorbent assay.
There was a reverse association between plasma 25(OH)D3 levels and cognitive impairment (OR = 2.15, 95% CI: 1.05–4.41, p < 0.05).
Chhetri et al., 2018 [34]
France
Cross-sectional studySubjects: 1680 older adults from the Multi-domain Alzheimer
Disease
Preventive Trial (MAPT)
Age: 70 years old and older
Blood samples were taken during enrollment and total plasma 25-
hydroxyvitamin (D3 and D2 forms) were measured using a
commercially available electro-chemiluminescence competitive
binding assay.
High vitamin D was associated with a reduced likelihood of physical limitation and cognitive impairment (OR = 0.97, 95% CI: 0.95–0.99, p = 0.011).
Hooshmand et al., 2014 [35]
Sweden
Cross-sectional studySubjects: 75 patients (29 with subjective cognitive impairment, 28 with mild cognitive impairment, 18 with
AD) referred to the Memory Clinic
Mean age: 61.6 years old
Plasma samples were obtained during the diagnostic workup. Plasma levels of 25(OH)D were determined using the DiaSorin immunoassay method.Elevated plasma 25(OH)D was significantly associated with better cognitive status (OR = 0.969, 95% CI: 0.948–0.990 per increase of 1 nmol/L of 25(OH)D).
Lee et al., 2017 [36]
Korea
Cross-sectional studySubjects: 2940 older adults from the Korean Urban Rural Elderly cohort study
Age: 65 years old and older
Blood samples were collected after an overnight fast and
stored at −80 °C until the time of analysis. Serum 25-hydroxyvitamin D (25[OH]D) levels were measured using a chemiluminescence immunoassay.
Lower 25(OH)D levels were significantly associated with cognitive impairment (OR = 1.81, 95% CI: 1.11–2.94, p = 0.017).
Llewellyn et al., 2011 [37]
United States
Cross-sectional studySubjects: 3396 older adults from the Third National Health and
Nutrition Examination Survey
Age: 65 years old and older
Blood samples were
collected, and serum 25(OH)D concentration was measured by
radioimmunoassay.
Participants who were severely 25(OH)D deficient were more likely to suffer from cognitive impairment (OR = 3.9, 95% CI: 1.5–10.4, p = 0.02).
Pavlovic et al., 2018 [41]
United States
Cross-sectional studySubjects: 4358 patients from the Cooper Clinic in Dallas
Age: 55–65 years old
Serum 25-hydroxyvitamin D (25(OH)D) concentration was measured by a DiaSorin liasion chemiluminescence analyzer.Low vitamin D was shown to be significantly associated with cognitive impairment
(OR = 1.24, 95% CI: 1.01–1.51,
P = 0.038).
Rosa et al., 2019 [39]
Brazil
Cross-sectional studySubjects: 165 older adults
Age: 80 years old and older
All blood samples were collected after a 12 h fast, and then the serum was stored at −20 °C until analysis. Serum levels of vitamin D (25-hydroxyvitamin D) were measured using chemiluminescent microparticle
immunoassay on the BitLab system.
Low vitamin D (≤18 ng mL−1) was significantly associated with a high risk of cognitive decline. Older adults with vitamin D levels > 19 ng mL−1 showed a lower prevalence of cognitive decline (Prevalence ratio = 0.59, 95% CI: 0.39–0.87).
Sakuma et al., 2018 [40]
Japan
Cross-sectional studySubjects: 740 patients (527 males and 385 females from the Project in Sado for Total Health (PROST))
Age: 65 years old and older
Blood samples were collected at the time of enrollment. Serum 25(OH)D levels were measured by a double-antibody radioimmunoassay (RIA2).Low serum 25(OH)D levels were independently associated with a higher prevalence of cognitive impairment (OR = 2.70, 95% CI: 1.38–5.28, p = 0.0110).
Vedak et al., 2015 [41]
India
Cross-sectional studySubjects: 86 older adults
Age: 50 years old and older
Blood samples were collected by venipuncture after overnight fasting, and then the serum was separated and stored at −80 °C until analysis. Serum levels of 25(OH)D were measured using kits from Immunodiagnostic Systems.Serum 25(OH)D levels showed a substantial positive correlation with cognitive domains, including attention, language, registration, and naming (p < 0.001), whereas, there was a moderately positive correlation with domains such as orientation, recall, remote memory, visuospatial, and verbal fluency (p < 0.001).
Chang et al., 2010 [42]
Taiwan
Cross-sectional studySubjects: 215 community-dwelling older adults (128 females, 87 males)
Age: 65–79 years old
Fasting bloods were collected and the serum specimens were stored at −80 °C until analysis. Serum 25(OH)D was measured by DiaSorin 25-Hydroxyvitamin D 125I RIA.Insufficient 25(OH)D status was strongly linked to frailty syndrome using the Fried Frailty Index (FFI) (OR = 10.74, 95% CI: 2.60–44.31).
Dokuzlar et al., 2017 [43]
Turkey
Cross-sectional studySubjects: 335 patients who attended geriatric polyclinics (88
frail, 156 prefrail, and controls)
Age: 60 years old and older
Serum 25-hydroxy-vitamin
D [25(OH)D] level was measured using the radioimmunoassay technique.
Level of 25(OH)D decreased as severity of frailty increased (p < 0.05).
Gutiérrez-Robledo et al., 2016 [21]
Mexico
Cross-sectional studySubjects: 331 community-dwelling older adults
Age: 70 years old and older
Peripheral blood samples were drawn, processed, and stored at −70 °C until analyses. 25(OH)-vitamin D serum levels were measured by a commercially available enzyme-linked
immunosorbent assay (ELISA).
Low 25(OH)-vitamin D levels were significantly associated with the probability of being frail as compared with those with sufficient vitamin D levels (OR = 8.95, 95% CI: 2.41–33.30).
Hirani et al., 2013 [44]
Australia
Cross-sectional studySubjects: 1659 community-dwelling older adults (males)
Age: 70 years old and older
Fasting blood samples were collected from participants in the morning of their clinic visit. Serum 25D and 1,25D levels were measured by manual radioimmunoassay using single batch reagents.Low serum 25-hydroxyvitamin D (OR = 2.66, 95% CI: 1.32–5.36, p = 0.006) and 1,25-dihydroxyvitamin D (OR = 1.86, 95% CI: 1.04–3.59, p = 0.04) levels were independently linked to frailty in older adults.
Pabst et al., 2015 [45]
Germany
Cross-sectional studySubjects: 940 older adults (478 males and 462 females) from KORA (Cooperative health research in the Region of Augsburg) Age study
Age: 65–90 years old
Serum total 25(OH)D was measured using enhanced chemiluminescence immunoassay.High levels of 25(OH)D were inversely associated with being prefrail or frail. The odds ratios (OR) with 95% confidence intervals (CI) were 0.52 (0.34–0.78) for levels of 15 to <20 ng/mL, 0.55 (0.37 to 0.81) for normal 25(OH)D levels of 20 to <30 ng/mL, and 0.32 (0.21 to 0.51) for serum levels in the highest range ≥30 ng/mL.
Alvarez-Ríos et al., 2015 [46]
Spain
Cross-sectional studySubjects: 592 participants
Median age: 74 years old
Serum concentrations of 25(OH)D from fasting blood were determined by a fully automated immunoassay 149 electrochemiluminescence system.Low levels of 25(OH)D were significantly associated with frailty (OR = 1.65, 95% CI: 1.02–2.67, p = 0.042).
O’Halloran et al., 2020 [47]
Ireland
Cross-sectional studySubjects: 4068 participants
Age: 50 years old and older
Non-fasting whole blood samples were collected between 09:30 AM and 16:30 PM by venipuncture and the plasma was then separated from the blood samples within 48 h of collection and archived at −80 °C until assayed.
Plasma 25-hydroxyvitamin D (25(OH)D) concentrations were
quantified using liquid chromatography tandem mass spectrometry.
All 3 measures of frailty were associated with lower levels of vitamin D (relative risk ratios (RRRs) = 0.51–0.75).
Wilhelm-Leen et al., 2010 [48]
United States
Cross-sectional studySubjects: 5048 participants from the Third National Health and Nutrition Survey (NHANES III)
Age: 60 years old and older
Blood samples were
collected, processed, and stored at −70 °C until analysis. Serum 25-hydroxyvitamin D was measured using the DiaSorin radioimmune assay kit.
Low serum 25-hydroxyvitamin D concentrations were associated with frailty amongst older adults (OR = 3.7, 95% CI: 2.1–6.8 amongst white older adults and OR = 4.0, 95% CI: 1.7–9.2 amongst non-white older adults).
Graf et al., 2014 [53]
Switzerland
Prospective studySubjects: 428 inpatients from the Geneva geriatric hospital
Age: 75 years old and older
The 25(OH)D level was performed from frozen plasma
obtained at the day of inclusion in the study and stored
at −80 °C. Participants were followed-up for two years. Plasma 25(OH)D levels were measured by electrochemiluminesence immunoassay using Cobas E601.
Vitamin D was not associated with cognitive status (RRRs = 0.96, 95% CI: 0.25–3.61, p = 0.948).
Granic et al., 2015 [49]
United Kingdom
Prospective studySubjects: 775 participants in the Newcastle 85 + Study
Age: 85 years old and older
Serum 25(OH)D was obtained from fasting morning
blood samples. Participants were followed-up at 1.5 and 3 years. Serum 25(OH)D was measured using the DiaSorin radioimmune assay kit.
Both low and high season-specific concentrations of 25(OH)D were linked with the increased risk of prevalent cognitive impairment (OR = 1.66, 95% CI: 1.06–2.60, p = 0.03; and OR = 1.62, 95% CI: 1.02 to 2.59, p = 0.04, respectively).
Matchar et al., 2016 [50]
China
Prospective studySubjects: 1202 cognitively intact older adults
Age: 60 years old and older
Fasting venous blood was collected, processed, and stored at −80 °C until analysis. The mean follow-up duration was 2.0 ± 0.2 years. Plasma 25(OH)D3 was measured using an enzyme-linked immunoassay by Immunodiagnostic Systems Limited.Low vitamin D levels were significantly associated with an increased risk of subsequent cognitive decline (OR = 2.0, 95% CI: 1.2–3.3) and impairment (OR = 3.2, 95% CI: 1.5–6.6).
Moon et al., 2015 [51]
Korea
Prospective studySubjects: 405 older adults from the Korean Longitudinal Study on Health and Aging (KLoSHA)
Age: 65 years old and older
Serum 25(OH)D concentrations were measured with ultra HPLC–tandem mass spectrometry. Participants were followed-up for 5 years.Severe vitamin D deficiency was independently associated with the future risk of MCI (hazard ratio (HR) = 7.13, 95% CI: 1.54–32.9, p = 0.012).
Slinin et al., 2012 [52]
United States
Prospective studySubjects: 6257 older adults (females)
Age: 65 years old and older
Fasting morning blood was collected, processed, and stored at −70 °C until analysis. Participants were followed-up for 4 years, and 25(OH)D 2 (ergocalciferol) and 25(OH)D 3 (cholecalciferol) were measured using mass spectrometry.Low 25(OH)D levels among older women were associated with a higher odd of global cognitive impairment (OR = 1.60, 95% CI: 1.05–2.42) and a higher risk of global cognitive decline (OR = 1.58, 95% CI: 1.12–2.22).
Buchebner et al., 2019 [54]
Sweden
Prospective studySubjects: 1044 community-dwelling women, aged 75 years with reassessments at ages 80 (n = 715) and 85 (n = 382) yearsNon-fasting serum samples were collected and stored at −80 °C. Participants were followed for 10 years. Serum 25(OH)D was assayed
using liquid chromatography-mass spectrophotometry
linked to an HPLC system.
The 25(OH)D insufficiency was associated with increased frailty in age 75 and 80 years (0.23 vs. 0.18, p < 0.001; and 0.32 vs. 0.25, p = 0.001, respectively). No association between 25(OH)D and frailty was observed at age 85 years (0.38 vs. 0.34, p = 0.187).
Buta et al., 2016 [56]
United States
Prospective studySubjects: 369 women from
the Women’s Health and Aging Study II
Age: 70–79 years old at baseline
Serum 25-hydroxyvitamin D (25[OH]D) was measured
using a radioreceptor assay. The mean duration of follow-up was 8.5 ± 3.7 years.
Low serum vitamin D concentration was associated with incident frailty in older women (HR = 2.77, 95% CI: 1.14–6.71, p = 0.02), but the relationship was not evident after accounting for the presence of cardiometabolic diseases (HR = 2.29, 95% CI: 0.92–5.69, p = 0.07).
Vogt et al., 2015 [55]
Germany
Prospective studySubjects: 727 older adults from KORA-Age study
Age: 65 years old and older
Non-fasting blood samples were collected at baseline and stored at −80 °C until analysis. Participants were followed for 2.9 ± 0.1 years. Serum total 25(OH)D were measured using enhanced chemiluminescence immunoassay.Participants with very low 25(OH)D levels (<15 ng/mL vs. ≥30 ng/mL) had significantly higher odds of prefrailty (OR = 2.43, 95% CI: 1.17–5.03) and prefrailty/frailty combined (OR = 2.53, 95% CI: 1.23–5.22), but not exclusively for frailty (OR = 2.63, 95% CI: 0.39–17.67).

3.3. Association of B Vitamins with Mild Cognitive Impairment, Frailty, and Cognitive Frailty

The association between B vitamins with mild cognitive impairment and frailty was reported in 10 studies (Table 4). Two cross-sectional studies reported that low folate levels were associated with an increased risk of mild cognitive impairment [57,58]. Furthermore, one retrospective, prospective study and case-control study, respectively, also found that low folate levels were linked to an increased risk of mild cognitive impairment [59,60,61]. Beyond that, two cross-sectional studies reported that low vitamin B12 levels were significantly associated with the risk of mild cognitive impairment [62,63], while one cross-sectional study by Soh et al. (2020) revealed that there was no significant association between low vitamin B12 and cognitive impairment [64]. In contrast, Rosa et al. (2019) found that high vitamin B12 levels were a risk factor for cognitive decline [36]. Other than that, one prospective and case-control study reported that increased homocysteine levels were associated with the risk of mild cognitive impairment [60,61]. In discussing frailty, one cross-sectional study by Dokuzlar et al. (2017) found that no association between vitamin B12 levels and frailty was evident [40]. The techniques that had been used for measuring serum or plasma vitamin B12 and folate included the immunoassay technique [57,59,60,61,62,63], vitamin kit [64], chemistry analyzer [43], and microbiological assays [47], whereas total plasma homocysteine was measured using the enzymatic assay [34] and immunoassay technique [60].

3.4. Association of Antioxidants with Mild Cognitive Impairment, Frailty, and Cognitive Frailty

There were six studies that investigated the association between antioxidants with mild cognitive impairment, frailty, and cognitive frailty (Table 5). One cross-sectional, prospective, and case-control study, respectively, found that low levels of vitamin E (tocopherol) were significantly associated with mild cognitive impairment [65,66,67]. Beyond that, one cross-sectional study by Mangialasche et al. (2013) reported that vitamin A deficiency was associated with an increased risk of mild cognitive impairment [68]. Furthermore, two cross-sectional studies also reported that low lutein and zeaxanthin were significantly associated with frailty [47,69]. However, only one cross-sectional study conducted by Rietman et al. (2019) reported that low levels of β-cryptoxanthin were significantly associated with the risk of cognitive frailty [69]. Serum levels of vitamins A and E were measured by high performance liquid chromatography (HPLC) [65,66,68].

3.5. Association of Protein with Mild Cognitive Impairment, Frailty, and Cognitive Frailty

The association between protein with mild cognitive impairment and frailty was reported in four studies, and all found that low serum albumin was significantly associated with mild cognitive impairment and frailty (Table 6). Two cross-sectional studies reported that low serum albumin was significantly associated with mild cognitive impairment [71,72]. Furthermore, one retrospective study conducted by Wang et al. (2018) among 1800 older adults, aged 60 years and older, revealed that low serum albumin was significantly associated with an increased risk of mild cognitive impairment [73]. Furthermore, one cross-sectional study by Dokuzlar et al. (2017) found that levels of albumin decreased as the severity of frailty increased (p < 0.05) [43]. Serum albumin was measured using a chemistry analyzer [71,72].

3.6. Association of Lipids with Mild Cognitive Impairment, Frailty, and Cognitive Frailty

There were three studies that investigated the association between lipids with mild cognitive impairment and frailty (Table 7). Low omega-3 index levels were significantly associated with mild cognitive impairment as reported in a cross-sectional study by Lukaschek et al. (2016) [74]. Other than that, one case-control study reported that the proportion of lower unsaturated fatty acids and higher saturated fatty acids were significantly associated with mild cognitive impairment [75]. Furthermore, Chhetri et al. (2018) also discovered that low n−3PUFA showed a higher likelihood of physical limitation [34]. Erythrocyte fatty acid composition was measured using gas chromatography [34,74,75].

4. Discussion

The purpose of the current scoping review was to map current evidence on the association of micronutrient deficiency in blood with cognitive impairment, frailty, and cognitive frailty among older adults. Figure 2 summarizes the findings on the association between micronutrient malnutrition with mild cognitive impairment, frailty, and cognitive frailty that was involved in the elderly. A previous review had shown that thirteen vitamins (i.e., vitamin A, thiamine, riboflavin, niacin, pantothenic acid, vitamin B6, biotin, folate, vitamin B12, vitamin C, vitamin D, vitamin E, and vitamin K) and three quasi-vitamins (i.e., choline, inositol, and carnitine) play a substantial role in ≥1 of 6 relevant pathways associated with Alzheimer’s disease (AD) [27]. Meanwhile, findings from this present review add on the evidence of the association between micronutrient malnutrition (i.e., vitamin D, B vitamins, antioxidants, protein, and lipids) and a broader scope of cognitive disorders, namely, cognitive impairment, frailty, and cognitive frailty among older adults. Comprehensive knowledge on the biomarkers that are specific to MCI, frailty, and cognitive frailty is essential to design appropriate preventive strategies. According to Orsitto et al. [76], older adults who were at risk of malnutrition were more likely to suffer from MCI. While Khater and Abouelezz [77] reported that MCI might be associated with nutritional risks in elderly patients.
In this review, the results from both the cross-sectional [33,34,35,36,37,38,39,40,41] and prospective [49,50,51,52] studies supported the evidence of lower vitamin D levels being significantly associated with mild cognitive impairment. For example, the cross-sectional study by Chei et al. among older adults aged 60 years and above showed that the risk of cognitive impairment was higher by 2.15 times among those with the lowest (5.7–31.6 nmol/L) vitamin D levels as compared to the highest (57.0–208.7 nmol/L) [33]. A prospective study involving 9704 women aged 65 years and older demonstrated that women with very low vitamin D (<25 nmol/L) levels had increased odds of global cognitive impairment at 1.60 times as compared with those who had sufficient vitamin D levels (≥75 nmol/L) [52]. Similarly, a meta-analysis by Etgen et al. also found that older adults with low vitamin D status showed an increased risk of cognitive impairment compared with normal vitamin D status by 2.39 times [78]. Furthermore, a double-blind, randomized, placebo-controlled trial study in China among older adults aged 65 years and older with MCI reported that vitamin D supplementation (800 IU/day) for 12 months appeared to improve cognitive function by reducing oxidative stress [79]. Older adults with cognitive impairment could have limited sunlight exposure as a result of living in nursing homes or being confined indoors, leading to lower vitamin D levels. However, even after adjusting these potential confounders, the odds ratio was statistically significant, emphasizing the robustness of the association between low plasma vitamin D and the increased odds of cognitive impairment [33].
There are various biological pathways that may describe the association between low vitamin D and mild cognitive impairment. First, the risk of cardiovascular disease, diabetes, and hypertension may be increased by vitamin D deficiency [80], and these conditions may in turn be correlated with cognitive impairment [81]. Secondly, vitamin D may play a role in brain detoxification pathways by reducing cellular calcium, inhibiting nitric oxide synthase synthesis, and protecting neurons from reactive oxygen species by increasing glutathione levels [82]. Thirdly, vitamin D induces neurogenesis and regulates the synthesis of neurotrophic factors that are essential for cell differentiation and survival [83]. As for the fourth association found, vitamin D is also an immunosuppressive agent and prevents autoimmune damage to the nervous system [82]. Lastly, vitamin D induces amyloid beta clearance and phagocytosis, and thus it protects against programmed cell death [84].
Folate is required for the synthesis of DNA and RNA nucleotides, the metabolism of amino acids, and the occurrence of methylation reactions in almost all tissues including the brain [85]. Results from three cross-sectional studies and one retrospective, one prospective, and a case-control study supported the evidence that low folate levels were significantly associated with an increased risk of mild cognitive impairment [57,58,59,60,61]. For example, a case-control study of individuals aged 60 years and older in China found that a higher serum folate level (>7 ng/mL) was associated with a lower risk of MCI (adjusted odds ratio 0.24, 95% CI: 0.11, 0.52, p = 0.000) [61]. The systematic and meta-analysis by Zhang et al. also supported that plasma/serum folate levels were lower in AD patients than those in controls with the standardized mean difference (SMD) at −0.60 (95% confidence interval (CI): −0.65, −0.55) [86]. Besides folate, vitamin B12 insufficiency is frequently linked to cognitive impairments [87]. Thus, results from the two cross-sectional studies supported the evidence of low vitamin B12 levels being significantly associated with the risk of mild cognitive impairment [62,63]. A systematic and meta-analysis of cross-sectional studies by Zhang et al. found higher levels of vitamin B12 (OR = 0.77, 95% CI = 0.61–0.97) being positive associated with better cognition, thus, it concurrently supported the current study [88]. Folate and vitamin B12 are required for homocysteine metabolism, and their deficiency results in elevated homocysteine concentration [89]. The results from one prospective and case-control study supported evidence that increased homocysteine levels were significantly associated with the risk of mild cognitive impairment [60,61]. A case-control study by Zhou et al. among older adults aged 60 years and older with and without MCI found that higher homocysteine levels were associated with the risk of MCI (p < 0.01) [61]. Our review findings were consistent with the previous meta-analysis that reported high homocysteine levels (risk ratios, RR = 1.93; 95% CI: 1.50–2.49) were particularly strong predictors of Alzheimer’s disease [90].
Possible mechanisms related to the association between folate and other B vitamins with mild cognitive impairment, particularly vitamin B12, play an important role in regulating gene expression and DNA synthesis, or specifically, as determinants of homocysteine detoxification and neurotransmitter synthesis [91]. Folate and vitamin B12 deficiencies can reduce the S-adenosyl methionine and increase plasma homocysteine, and these effects may lead to cognitive impairment through the oxidation of functional and structural neuron and endothelium [89], as well as the inhibition of methylation-dependent reactions that include synthesis of the neurotransmitter [92]. The possible mechanisms of homocysteine neurotoxicity involve disruptions in methylation and/or redox potential, thus stimulating calcium influx, irregular amyloid, and tau protein accumulation [93], which eventually can result in apoptotic events and neuronal death [94]. Elevated homocysteine contributes to oxidative stress and cerebrovascular and neurological lesions, cognitive and memory decline, thus playing a crucial role in the pathogenesis of neurodegenerative diseases [95].
Results from one cross-sectional, prospective, and case-control study support evidence of low levels of vitamin E (tocopherol) being significantly associated with mild cognitive impairment [65,66,67]. A population-based prospective study (CAIDE) among 140 older adults reported that the risk of cognitive impairment was lower among subjects in the middle tertile (>0.295 and <0.05 µmol/mmol) of the γ-tocopherol/cholesterol ratio than in those in the lowest tertile (≤0.295 µmol/mmol): the multi-adjusted odds ratio (OR) with 95% confidence interval (CI) at 0.27 (0.10–0.78) [66]. This finding, that is also supported by the systematic and meta-analysis of cohort studies, reported that some food intake was related with a decrease in dementia, such as vitamin E (RR: 0.80 95% CI: [0.65–0.9], p = 0.034) [96]. The mechanisms that may describe the association between low vitamin E and the risk of mild cognitive impairment are its role as an antioxidant in the human body that protects the central nervous system (CNS) from free radical-mediated damage [97]. Vitamin E also has biological properties such as anti-inflammatory activity and cell signal regulation which may be important for neuroprotection [98].
Results from one cross-sectional study supported the evidence that vitamin A deficiency was associated with an increased risk of mild cognitive impairment. Shahar et al. have found that one of the predictors of MCI was vitamin A deficiency (adjusted OR = 3.253; 95% CI = 0.972–10.886; p < 0.05) [68]. Wołoszynowska-Fraser et al. have made a review about vitamin A and retinoic acid in cognition and cognitive diseases and presented the conclusion that vitamin A and retinoic acid were essential for learning, memory, and other cognitive processes [99]. Possible mechanisms’ pathways associated with the relationship between serum vitamin A levels and cognitive function are described below. Firstly, antioxidation, anti-inflammatory, anti-cholinesterase, and memory-restorative functions have been proposed for all-trans retinoic acid in the carboxylic form known as vitamin A [100]. Secondly, retinoic acid is responsible for neuroimmunological functions and interacts with other signaling mechanisms regulated by the nuclear receptor. Thirdly, retinoic acid is associated with regeneration and cognition [101]. Lastly, vitamin A may be able to suppress the formation of beta-amyloid fibrin [102].
Results from two cross-sectional studies supported the evidence of low serum albumin being significantly associated with mild cognitive impairment [71,72]. Based on a national population-based study in England among 1752 older adults aged 65 years and older, it was reported that the odds ratios (95% confidence intervals) for cognitive impairment in the first (2.2–3.8 g/dL), second (3.9–4.0 g/dL), and third (4.1–4.3 g/dL) quartiles of serum albumin compared with the fourth quartile (4.4–5.3 g/dL) were 2.5 (1.3–5.1), 1.7 (0.9–3.5), and 1.5 (0.7–2.9) [71]. A previous systematic review also supported that low or decreasing serum albumin was a predictive factor of increased mortality [103]. Malnutrition has negative consequences for dementia patients, such as increased morbidity and mortality and decreased quality of life [104]. Several mechanisms have been proposed to explain the effects of serum albumin on patients with mild cognitive impairment risk. Firstly, serum albumin is correlated with the nutritional condition of older people [105], and persistent malnutrition plays a vital role in cognitive impairment [106]. Second, serum albumin is essential to maintain colloid osmotic pressure and blood volume in the human body [107]. Lower albumin levels interfere with the adequate delivery of blood to the central nervous system and can lead to cognitive impairment. Thirdly, oxidative stress injury is a non-negligible cognitive impairment pathogenic cause [108]. Serum albumin has a high antioxidant function [109], and a reduction in its amount contributes to the oxidation/antioxidation imbalance and cognitive impairment.
Results from one cross-sectional study supported the evidence that low omega-3 index levels were significantly associated with mild cognitive impairment [74]. A meta-analysis by Beydoun et al. has also found that higher intake of n-3 fatty acids as a protective factor vs. lower intake with RR was 95% CI: RR = 0.67(0.47,0.96) [90]. Several possible mechanisms have been proposed related to the association between low omega-3 and mild cognitive impairment risk. There is evidence that indicates that omega-3 polyunsaturated fatty acids (PUFA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) may have neuroprotective properties [110]. Omega-3 PUFA levels in the brain appear to decrease with aging, indicating that low levels of EPA and DHA could lead to memory loss and other cognitive functions [111]. Both EPA and DHA may also have a role in synaptic plasticity, neurogenesis, cognition, and vascular health [112]. The benefits of DHA could be due to its derivative neuroprotection D1 NPD1, which helps to promote membrane fluidity, regulate apoptosis, and modulate inflammation [113]. Likewise, EPA plays a key role in the regulation of blood flow and inflammation [114].
According to a systematic review by Lorenzo-lopez et al. [115], malnutrition or poor nutrition may cause frailty or vice versa, which may cause malnutrition or poor nutrition among older adults. Other mediating factors that may have influenced the association between the two variables include poor dentition, swallowing problems, reduced sense of smell or taste, and deteriorating functional capacity. In this current review, results from eight cross-sectional studies supported the evidence that low levels of vitamin D were significantly associated with frailty [21,42,43,44,45,47,48]. Another two prospective studies supported that low levels of vitamin D were significantly associated with frailty [54,55]. The results of this review are in line with a meta-analysis by Zhou et al. that suggested low levels of vitamin D were significantly associated with the risk of frailty: OR of frailty for the lowest versus the highest level of vitamin D was 1.27 (95% CI = 1.17–1.38) [116]. A study conducted by Hirani et al. [44] among community-residing men reported that the association between frailty and both low 25D and 1,25D levels remained significant, even after adjustments for other measures such as self-reported health and a range of health conditions that could also affect the ability to spend time outdoors and access sun exposure. Two cross-sectional studies supported evidence that low lutein and zeaxanthin were significantly associated with frailty [47,69]. A systematic review made by Zupo et al. also reported that higher dietary and plasma levels of carotenoids (α-carotene, β-carotene, lutein, lycopene, β-cryptoxanthin, and total carotenoids) were found to reduce the odds of physical frailty [18]. One cross-sectional study supported evidence that a low level of albumin was significantly associated with the risk of frailty [43]. Our review findings were consistent with a meta-analysis by Mailliez et al. that concluded frail individuals had lower plasmatic albumin levels with standardized mean difference (SMD): −0.62 (−0.84;−0.41) than robust individuals [117]. Only one cross-sectional study supported evidence of low levels of β-cryptoxanthin that were significantly associated with the risk of cognitive frailty [69]. Previous systematic reviews highlighted the importance of considering carotenoids as biological markers to monitor micronutrient status and to adopt recommendations of increased fruit and vegetable intake for intervention purposes, prevention, and better management of disability among older adults [18].
There are several possible biological mechanisms that may describe the correlation between low vitamin D levels and frailty. Low vitamin D levels are associated with a higher risk of incident mobility limitation and disability [118] due to the effect of vitamin D on the metabolism of muscle cells, including the transport of calcium, inorganic phosphate absorption of energy-rich phosphate compounds, and protein synthesis [119]. Low vitamin D is related to an increased risk of Th1 cytokine-mediated autoimmune disorders that include rheumatoid arthritis [120]. Evidence also shows that inflammation plays a key role in the pathophysiology of frailty via an irregular, low-grade chronic inflammatory response [121].
Possible mechanisms associated with lutein and zeaxanthin and frailty risk are xanthophyll carotenoids that serve as important antioxidants and anti-inflammatory compounds [122], with a potentially protective role in chronic aging diseases that include bone health [123]. Carotenoid deficiency can lead to chronic diseases through multiple physiological systems as a central feature of frailty [47]. Previous research has reported that both inflammation and oxidative stress are correlated with frailty [124].
The mechanism that may explain the association between serum albumin and frailty risk is the indication of protein catabolism with the loss of muscle mass through low serum albumin. Additionally, low albumin levels could also suggest that systemic inflammation as previously mentioned plays a role in the development of frailty [125]. Low serum albumin can also imply the presence of high oxidative stress and its association with frailty, which further promotes the role of oxidative stress in frailty [126].

4.1. Research Gaps

A number of gaps in knowledge are apparent from this scoping review. Firstly, most of the studies that evaluated the association between blood micronutrient profiles, mild cognitive impairment, and frailty were cross-sectional studies [21,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,57,58,62,63,64,65,67,68,69,72,74,75]. In fact, case-control studies cannot demonstrate causality [61]. Hence, future prospective studies and randomized controlled trials need to be conducted to identify a potential direct causal relationship between micronutrient deficiency, mild cognitive impairment, and frailty. Neuroimaging and neuropathological studies at the molecular level would also be useful to identify the underlying mechanisms for these associations. Presently, we designed a randomized control trial study to determine the effectiveness of a multidomain intervention among older adults with cognitive frailty involving nutrition, psychosocial, physical activity, cognitive training, and management of metabolic and vascular risk factors modules [127].
Secondly, a small sample size of published studies may have affected the statistical power of the analyses produced [35,41,45,55,56,65,66,67,75]. Thus, a larger sample size is required in future studies to confirm the association between specific blood micronutrient deficiencies and mild cognitive impairment and/or frailty.
Thirdly, several studies were non-randomized; thus, these studies were not representative of the general population of older adults including patients from memory clinics, with the majority of subjects being farmers and housewives, a highly educated preventive medicine population, as well as hospital-based patients [35,38,40,52,58,65]. Therefore, future studies should also carefully consider participants’ settings in the study design, such as their ethnic group and geographical areas that would best represent the general population of older adults.
Lastly, there were also unmeasured confounding factors that might have affected the results, such as information on supplement intake, dietary factors, direct sun exposure, and physical activity [33,35,36,50,57,64]. Thus, future studies need to include these possible confounding factors because these confounding variables cannot be excluded.

4.2. Strengths and Limitations

This review is a current analysis of studies from 2010 to 2021 that investigated the association between micronutrient malnutrition with mild cognitive impairment, frailty, and cognitive frailty among older adults. However, the limitation of this review is that it only included articles that were published in English, and thus, other related research published in other languages may have been overlooked. Furthermore, this scoping review is a summary of publications with minimal-to-no analysis such as a meta-analysis. Hence, a future systematic review would prove the evidence on the association between micronutrient deficiency in blood and MCI, frailty, and CF.

5. Conclusions

This scoping review has highlighted the relationship between low levels of vitamin B12, vitamin A, omega fatty acid, vitamin D, and albumin and mild cognitive impairment based on published cross-sectional studies. However, the associations of folate, vitamin D, and homocysteine with mild cognitive impairment based on prospective studies are still limited. Furthermore, low levels of vitamin D, lutein, zeaxanthin, and albumin were significantly associated with frailty based on previous cross-sectional studies. In contrast, only one prospective study found that low levels of vitamin D were significantly associated with frailty. For cognitive frailty, low levels of β-cryptoxanthin and zeaxanthin were significantly associated with the risk of cognitive frailty based on only one cross-sectional study. The majority of the studies on the association between micronutrient malnutrition and mild cognitive impairment, frailty, and cognitive frailty in this review consisted of cross-sectional studies. Thus, future prospective studies and randomized controlled trials need to be conducted to identify a potential causal relationship between micronutrient deficiency and mild cognitive impairment, frailty, and cognitive frailty needs. Furthermore, several factors such as sample size calculation, participant settings, and possible confounding factors need to be considered when conducting future research.

Author Contributions

N.M.K.: conceptualization, methodology, formal analysis, resources, literature search, data analysis, writing review. H.H.: conceptualization, methodology, validation, writing review and editing, supervision. S.S.: conceptualization, methodology, validation, writing review and editing, supervision. M.F.: writing—review. All authors have read and agreed to the published version of the manuscript.

Funding

This study was funded by the Ministry of Higher Education of Malaysia under the Long Term Research Grant Scheme (LRGS/1/2019/UM-UKM/1/4).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Acknowledgments

We would like to thank the Universiti Kebangsaan Malaysia librarian for their guidance and advice in the literature search.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Kelaiditi, E.; Cesari, M.; Canevelli, M.; Abellan van Kan, G.; Ousset, P.-J.; Gillette-Guyonnet, S.; Ritz, P.; Duveau, F.; Soto, M.E.; Provencher, V.; et al. Cognitive Frailty: Rational and Definition from an (I.A.N.A./I.A.G.G.) International Consensus Group. J. Nutr. Health Aging 2013, 17, 726–734. [Google Scholar] [CrossRef]
  2. Feng, L.; Shwe, M.; Nyunt, Z.; Gao, Q.; Feng, L. Cognitive Frailty and Adverse Health Outcomes: Findings From the Singapore Longitudinal Ageing Studies ( SLAS ). J. Am. Med. Dir. Assoc. 2017, 18, 252–258. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Fried, L.P.; Tangen, C.M.; Walston, J.; Newman, A.B.; Hirsch, C.; Gottdiener, J.; Seeman, T.; Tracy, R.; Kop, W.J.; Burke, G.; et al. Frailty in Older Adults: Evidence for a Phenotype. J. Gerontol.-Ser. A Biol. Sci. Med. Sci. 2001, 56, 146–157. [Google Scholar] [CrossRef] [PubMed]
  4. Gauthier, S.; Reisberg, B.; Zaudig, M.; Petersen, R.C.; Ritchie, K.; Broich, K.; Belleville, S.; Brodaty, H.; Bennett, D.; Chertkow, H.; et al. Mild Cognitive Impairment. Lancet 2006, 367, 1262–1270. [Google Scholar] [CrossRef] [PubMed]
  5. Feng, L.; Nyunt, M.S.Z.; Gao, Q.; Feng, L.; Lee, T.S.; Tsoi, T.; Chong, M.S.; Lim, W.S.; Collinson, S.; Yap, P.; et al. Physical Frailty, Cognitive Impairment, and the Risk of Neurocognitive Disorder in the Singapore Longitudinal Ageing Studies. J. Gerontol.-Ser. A Biol. Sci. Med. Sci. 2017, 72, 369–375. [Google Scholar] [CrossRef] [Green Version]
  6. O’Caoimh, R.; Sezgin, D.; O’Donovan, M.R.; William Molloy, D.; Clegg, A.; Rockwood, K.; Liew, A. Prevalence of Frailty in 62 Countries across the World: A Systematic Review and Meta-Analysis of Population-Level Studies. Age Ageing 2021, 50, 96–104. [Google Scholar] [CrossRef]
  7. Pais, R.; Ruano, L.; Carvalho, O.P.; Barros, H. Global Cognitive Impairment Prevalence and Incidence in Community Dwelling Older Adults—A Systematic Review. Geriatrics 2020, 5, 84. [Google Scholar] [CrossRef] [PubMed]
  8. Vanoh, D.; Shahar, S.; Din, N.C.; Omar, A.; Vyrn, C.A.; Razali, R.; Ibrahim, R.; Hamid, T.A. Predictors of Poor Cognitive Status among Older Malaysian Adults: Baseline Findings from the LRGS TUA Cohort Study. Aging Clin. Exp. Res. 2017, 29, 173–182. [Google Scholar] [CrossRef] [PubMed]
  9. Kiiti Borges, M.; Oiring de Castro Cezar, N.; Silva Santos Siqueira, A.; Yassuda, M.; Cesari, M.; Aprahamian, I. The Relationship between Physical Frailty and Mild Cognitive Impairment in the Elderly: A Systematic Review. J. Frailty Aging 2019, 8, 192–197. [Google Scholar] [CrossRef] [PubMed]
  10. Fougère, B.; Daumas, M.; Lilamand, M.; Sourdet, S.; Delrieu, J.; Vellas, B.; Abellan van Kan, G. Association Between Frailty and Cognitive Impairment: Cross-Sectional Data from Toulouse Frailty Day Hospital. J. Am. Med. Dir. Assoc. 2017, 18, 990.e1–990.e5. [Google Scholar] [CrossRef] [PubMed]
  11. Rivan, N.F.M.; Shahar, S.; Rajab, N.F.; Singh, D.K.A.; Din, N.C.; Mahadzir, H.; Sakian, N.I.M.; Ishak, W.S.; Rahman, M.H.A.; Mohammed, Z.; et al. Incidence and Predictors of Cognitive Frailty among Older Adults: A Community-Based Longitudinal Study. Int. J. Environ. Res. Public Health 2020, 17, 1547. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Zainuddin, N.S.; Husin, M.H.; Ahmad, N.H.; Yun Hua, W.; Wan Chien, H.; Shahar, S.; Ismail, M.; Ajit Singh, D.K. Association between Nutritional Status, Food Insecurity and Frailty among Elderly with Low Income. J. Sains Kesihat. Malaysia 2017, 15, 51–60. [Google Scholar] [CrossRef]
  13. Badrasawi, M.; Shahar, S.; Kaur Ajit Singh, D. Risk Factors of Frailty Among Multi-Ethnic Malaysian Older Adults. Int. J. Gerontol. 2017, 11, 154–160. [Google Scholar] [CrossRef]
  14. Khairiah, K.; Mooi, C.S.; Hamid, T.A. Prevalence and Factors Associated with Mild Cognitive Impairment on Screening in Older Malaysians. Dusunen Adam 2016, 29, 298–306. [Google Scholar] [CrossRef] [Green Version]
  15. Hussin, N.M.; Shahar, S.; Yahya, H.M.; Din, N.C.; Singh, D.K.A.; Omar, M.A. Incidence and Predictors of Mild Cognitive Impairment (MCI) within a Multi-Ethnic Asian Populace: A Community-Based Longitudinal Study. BMC Public Health 2019, 19, 1159. [Google Scholar] [CrossRef] [Green Version]
  16. Bauer, J.; Biolo, G.; Cederholm, T.; Cesari, M.; Cruz-Jentoft, A.J.; Morley, J.E.; Phillips, S.; Sieber, C.; Stehle, P.; Teta, D.; et al. Evidence-Based Recommendations for Optimal Dietary Protein Intake in Older People: A Position Paper from the Prot-Age Study Group. J. Am. Med. Dir. Assoc. 2013, 14, 542–559. [Google Scholar] [CrossRef]
  17. Iolascon, G.; Gimigliano, R.; Bianco, M.; De Sire, A.; Moretti, A.; Giusti, A.; Malavolta, N.; Migliaccio, S.; Migliore, A.; Napoli, N.; et al. Are Dietary Supplements and Nutraceuticals Effective for Musculoskeletal Health and Cognitive Function? A Scoping Review. J. Nutr. Health Aging 2016, 21, 527–538. [Google Scholar] [CrossRef]
  18. Zupo, R.; Castellana, F.; De Nucci, S.; Sila, A.; Aresta, S.; Buscemi, C.; Randazzo, C.; Buscemi, S.; Triggiani, V.; De Pergola, G.; et al. Role of Dietary Carotenoids in Frailty Syndrome: A Systematic Review. Biomedicines 2022, 10, 632. [Google Scholar] [CrossRef] [PubMed]
  19. Cruz-Jentoft, A.J.; Kiesswetter, E.; Drey, M.; Sieber, C.C. Nutrition, Frailty, and Sarcopenia. Aging Clin. Exp. Res. 2017, 29, 43–48. [Google Scholar] [CrossRef]
  20. Lee, S.L.; Thomas, P.; Fenech, M. Genome Instability Biomarkers and Blood Micronutrient Risk Profiles Associated with Mild Cognitive Impairment and Alzheimer’s Disease. Mutat. Res.-Fundam. Mol. Mech. Mutagen. 2015, 776, 54–83. [Google Scholar] [CrossRef]
  21. Gutiérrez-Robledo, L.M.; Ávila-Funes, J.A.; Amieva, H.; Meillon, C.; Acosta, J.L.; Navarrete-Reyes, A.P.; Torres-Carrillo, N.; Muñoz-Valle, J.F.; Torres-Carrillo, N.M. Association of Low Serum 25-Hydroxyvitamin D Levels with the Frailty Syndrome in Mexican Community-Dwelling Elderly. Aging Male 2016, 19, 58–63. [Google Scholar] [CrossRef]
  22. Adachi, Y.; Ono, N.; Imaizumi, A.; Muramatsu, T.; Andou, T.; Shimodaira, Y.; Nagao, K.; Kageyama, Y.; Mori, M.; Noguchi, Y.; et al. Plasma Amino Acid Profile in Severely Frail Elderly Patients in Japan. Int. J. Gerontol. 2018, 12, 290–293. [Google Scholar] [CrossRef]
  23. Darwish, H.; Zeinoun, P.; Ghusn, H.; Khoury, B.; Tamim, H.; Khoury, S.J. Serum 25-Hydroxyvitamin D Predicts Cognitive Performance in Adults. Neuropsychiatr. Dis. Treat. 2015, 11, 2217–2223. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Dyall, S.C. Long-Chain Omega-3 Fatty Acids and the Brain: A Review of the Independent and Shared Effects of EPA, DPA and DHA. Front. Aging Neurosci. 2015, 7, 52. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Ng, T.P.; Feng, L.; Nyunt, M.S.Z.; Feng, L.; Niti, M.; Tan, B.Y.; Chan, G.; Khoo, S.A.; Chan, S.M.; Yap, P.; et al. Nutritional, Physical, Cognitive, and Combination Interventions and Frailty Reversal among Older Adults: A Randomized Controlled Trial. Am. J. Med. 2015, 128, 1225–1236.e1. [Google Scholar] [CrossRef] [Green Version]
  26. Ngandu, T.; Lehtisalo, J.; Solomon, A.; Levälahti, E.; Ahtiluoto, S.; Antikainen, R.; Bäckman, L.; Hänninen, T.; Jula, A.; Laatikainen, T.; et al. A 2 Year Multidomain Intervention of Diet, Exercise, Cognitive Training, and Vascular Risk Monitoring versus Control to Prevent Cognitive Decline in at-Risk Elderly People (FINGER): A Randomised Controlled Trial. Lancet 2015, 385, 2255–2263. [Google Scholar] [CrossRef] [PubMed]
  27. Fenech, M. Vitamins Associated with Brain Aging, Mild Cognitive Impairment, and Alzheimer Disease: Biomarkers, Epidemiological and Experimental Evidence, Plausible Mechanisms, and Knowledge Gaps. Adv. Nutr. 2017, 8, 958–970. [Google Scholar] [CrossRef] [Green Version]
  28. Arksey, H.; O’Malley, L. Scoping Studies: Towards a Methodological Framework. Int. J. Soc. Res. Methodol. Theory Pract. 2005, 8, 19–32. [Google Scholar] [CrossRef] [Green Version]
  29. Munn, Z.; Peters, M.D.J.; Stern, C.; Tufanaru, C.; McArthur, A.; Aromataris, E. Systematic Review or Scoping Review? Guidance for Authors When Choosing between a Systematic or Scoping Review Approach. BMC Med. Res. Methodol. 2018, 18, 143. [Google Scholar] [CrossRef]
  30. van Niekerk, L.; Manderson, L.; Balabanova, D. The Application of Social Innovation in Healthcare: A Scoping Review. Infect. Dis. Poverty 2021, 10, 26. [Google Scholar] [CrossRef]
  31. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; Altman, D.; Antes, G.; Atkins, D.; Barbour, V.; Barrowman, N.; Berlin, J.A.; et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009, 6, e1000097. [Google Scholar] [CrossRef] [Green Version]
  32. Song, J.W.; Chung, K.C. Nihms-237355. Plast. Reconstr. Surg. 2010, 126, 2234–2242. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Chei, C.L.; Raman, P.; Yin, Z.X.; Shi, X.; Zeng, Y.; Matchar, D.B. Vitamin D Levels and Cognition in the Elderly Population in China. J. Am. Geriatr. Soc. 2014, 141, 520–529. [Google Scholar] [CrossRef]
  34. Chhetri, J.K.; de Souto Barreto, P.; Soriano, G.; Gennero, I.; Cantet, C.; Vellas, B. Vitamin D, Homocysteine and N−3PUFA Status According to Physical and Cognitive Functions in Older Adults with Subjective Memory Complaint: Results from Cross-Sectional Study of the MAPT Trial. Exp. Gerontol. 2018, 111, 71–77. [Google Scholar] [CrossRef] [PubMed]
  35. Hooshmand, B.; Lökk, J.; Solomon, A.; Mangialasche, F.; Miralbell, J.; Spulber, G.; Annerbo, S.; Andreasen, N.; Winblad, B.; Cedazo-Minguez, A.; et al. Vitamin D in Relation to Cognitive Impairment, Cerebrospinal Fluid Biomarkers, and Brain Volumes. Journals Gerontol.-Ser. A Biol. Sci. Med. Sci. 2014, 69, 1132–1138. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Lee, E.Y.; Lee, S.J.; Kim, K.M.; Yun, Y.M.; Song, B.M.; Kim, J.E.; Kim, H.C.; Rhee, Y.; Youm, Y.; Kim, C.O. Association of Metabolic Syndrome and 25-Hydroxyvitamin D with Cognitive Impairment among Elderly Koreans. Geriatr. Gerontol. Int. 2017, 17, 1069–1075. [Google Scholar] [CrossRef]
  37. Llewellyn, D.J.; Lang, I.A.; Langa, K.M.; Melzer, D. Vitamin D and Cognitive Impairment in the Elderly U.S. Population. J. Gerontol.-Ser. A Biol. Sci. Med. Sci. 2011, 66 A, 59–65. [Google Scholar] [CrossRef] [Green Version]
  38. Pavlovic, A.; Abel, K.; Barlow, C.E.; Farrell, S.W.; Weiner, M.; DeFina, L.F. The Association between Serum Vitamin d Level and Cognitive Function in Older Adults: Cooper Center Longitudinal Study. Prev. Med. 2018, 113, 57–61. [Google Scholar] [CrossRef] [PubMed]
  39. da Rosa, M.I.; Beck, W.O.; Colonetti, T.; Budni, J.; Falchetti, A.C.B.; Colonetti, L.; Coral, A.S.; Meller, F.O. Association of Vitamin D and Vitamin B12 with Cognitive Impairment in Elderly Aged 80 Years or Older: A Cross-Sectional Study. J. Hum. Nutr. Diet. 2019, 32, 518–524. [Google Scholar] [CrossRef]
  40. Sakuma, M.; Kitamura, K.; Endo, N.; Ikeuchi, T.; Yokoseki, A.; Onodera, O.; Oinuma, T.; Momotsu, T.; Sato, K.; Nakamura, K.; et al. Low Serum 25-Hydroxyvitamin D Increases Cognitive Impairment in Elderly People. J. Bone Miner. Metab. 2019, 37, 368–375. [Google Scholar] [CrossRef]
  41. Vedak, T.K.; Ganwir, V.; Shah, A.B.; Pinto, C.; Lele, V.R.; Subramanyam, A.; Shah, H.; Deo, S.S. Vitamin D as a Marker of Cognitive Decline in Elderly Indian Population. Ann. Indian Acad. Neurol. 2015, 18, 314–319. [Google Scholar] [CrossRef] [PubMed]
  42. Chang, C.I.; Chan, D.C.; Kuo, K.N.; Hsiung, C.A.; Chen, C.Y. Vitamin D Insufficiency and Frailty Syndrome in Older Adults Living in a Northern Taiwan Community. Arch. Gerontol. Geriatr. 2010, 50, S17–S21. [Google Scholar] [CrossRef]
  43. Dokuzlar, Ö. Association between Serum Vitamin B12 Levels and Frailty in Older Adults. North. Clin. Istanb. 2017, 4, 22–28. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Hirani, V.; Naganathan, V.; Cumming, R.G.; Blyth, F.; Le Couteur, D.G.; Handelsman, D.J.; Waite, L.M.; Seibel, M.J. Associations between Frailty and Serum 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Concentrations in Older Australian Men: The Concord Health and Ageing in Men Project. J. Gerontol.-Ser. A Biol. Sci. Med. Sci. 2013, 68, 1112–1121. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Pabst, G.; Zimmermann, A.K.; Huth, C.; Koenig, W.; Ludwig, T.; Zierer, A.; Peters, A.; Thorand, B. Association of Low 25-Hydroxyvitamin D Levels with the Frailty Syndrome in an Aged Population: Results from the KORA-Age Augsburg Study. J. Nutr. Health Aging 2015, 19, 258–264. [Google Scholar] [CrossRef]
  46. Alvarez-Ríos, A.I.; Guerrero, J.M.; García-García, F.J.; Rodríguez-Mañas, L.; Medrano-Campillo, P.; de la Torre Lanza, M.A.; Alvarez-Sánchez, N.; Carrillo-Vico, A. Associations between Frailty and Serum N-Terminal Propeptide of Type I Procollagen and 25-Hydroxyvitamin D in Older Spanish Women: The Toledo Study for Healthy Aging. Exp. Gerontol. 2015, 69, 79–84. [Google Scholar] [CrossRef] [PubMed]
  47. O’Halloran, A.M.; Laird, E.J.; Feeney, J.; Healy, M.; Moran, R.; Beatty, S.; Nolan, J.M.; Molloy, A.M.; Kenny, R.A. Circulating Micronutrient Biomarkers Are Associated With 3 Measures of Frailty: Evidence from the Irish Longitudinal Study on Ageing. J. Am. Med. Dir. Assoc. 2020, 21, 240–247.e5. [Google Scholar] [CrossRef] [Green Version]
  48. Wilhelm-Leen, E.R.; Hall, Y.N.; Deboer, I.H.; Chertow, G.M. Vitamin D Deficiency and Frailty in Older Americans. J. Intern. Med. 2010, 268, 171–180. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  49. Granic, A.; Hill, T.R.; Kirkwood, T.B.L.; Davies, K.; Collerton, J.; Martin-Ruiz, C.; von Zglinicki, T.; Saxby, B.K.; Wesnes, K.A.; Collerton, D.; et al. Serum 25-Hydroxyvitamin D and Cognitive Decline in the Very Old: The Newcastle 85+ Study. Eur. J. Neurol. 2015, 22, 106–115. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  50. Matchar, D.B.; Chei, C.L.; Yin, Z.X.; Koh, V.; Chakraborty, B.; Shi, X.M.; Zeng, Y. Vitamin D Levels and the Risk of Cognitive Decline in Chinese Elderly People: The Chinese Longitudinal Healthy Longevity Survey. J. Gerontol.-Ser. A Biol. Sci. Med. Sci. 2016, 71, 1363–1368. [Google Scholar] [CrossRef]
  51. Moon, J.H.; Lim, S.; Han, J.W.; Kim, K.M.; Choi, S.H.; Kim, K.W.; Jang, H.C. Serum 25-Hydroxyvitamin D Level and the Risk of Mild Cognitive Impairment and Dementia: The Korean Longitudinal Study on Health and Aging (KLoSHA). Clin. Endocrinol. 2015, 83, 36–42. [Google Scholar] [CrossRef] [PubMed]
  52. Slinin, Y.; Paudel, M.; Taylor, B.C.; Ishani, A.; Rossom, R.; Yaffe, K.; Blackwell, T.; Lui, L.Y.; Hochberg, M.; Ensrud, K.E. Association between Serum 25(OH) Vitamin D and the Risk of Cognitive Decline in Older Women. J. Gerontol.-Ser. A Biol. Sci. Med. Sci. 2012, 67 A, 1092–1098. [Google Scholar] [CrossRef] [Green Version]
  53. Graf, C.E.; Rossi, C.; Giannelli, S.V.; Nobari, B.H.; Gold, G.; Herrmann, F.R.; Zekry, D. Vitamin D Is Not Associated with Cognitive Status in a Cohort of Very Old Hospitalized Patients. J. Alzheimer’s Dis. 2014, 42, S53–S61. [Google Scholar] [CrossRef] [PubMed]
  54. Buchebner, D.; Bartosch, P.; Malmgren, L.; McGuigan, F.E.; Gerdhem, P.; Akesson, K.E. Association between Vitamin D, Frailty, and Progression of Frailty in Community-Dwelling Older Women. J. Clin. Endocrinol. Metab. 2019, 104, 6139–6147. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Vogt, S.; Decke, S.; de Las Heras Gala, T.; Linkohr, B.; Koenig, W.; Ladwig, K.H.; Peters, A.; Thorand, B. Prospective Association of Vitamin D with Frailty Status and All-Cause Mortality in Older Adults: Results from the KORA-Age Study. Prev. Med. 2015, 73, 40–46. [Google Scholar] [CrossRef]
  56. Buta, B.; Choudhury, P.P.; Xue, Q.L.; Chaves, P.; Bandeen-Roche, K.; Shardell, M.; Semba, R.D.; Walston, J.; Michos, E.D.; Appel, L.J.; et al. The Association of Vitamin D Deficiency and Incident Frailty in Older Women: The Role of Cardiometabolic Diseases. J. Am. Geriatr. Soc. 2017, 65, 619–624. [Google Scholar] [CrossRef] [Green Version]
  57. Castillo-Lancellotti, C.; Margozzini, P.; Valdivia, G.; Padilla, O.; Uauy, R.; Rozowski, J.; Tur, J.A. Serum Folate, Vitamin B12 and Cognitive Impairment in Chilean Older Adults. Public Health Nutr. 2015, 18, 2600–2608. [Google Scholar] [CrossRef] [Green Version]
  58. Kim, G.; Kim, H.; Kim, K.N.; Son, J.I.; Kim, S.Y.; Tamura, T.; Chang, N. Relationship of Cognitive Function with B Vitamin Status, Homocysteine, and Tissue Factor Pathway Inhibitor in Cognitively Impaired Elderly: A Cross-Sectional Survey. J. Alzheimer’s Dis. 2013, 33, 853–862. [Google Scholar] [CrossRef]
  59. Baroni, L.; Bonetto, C.; Rizzo, G.; Bertola, C.; Caberlotto, L.; Bazzerla, G. Association between Cognitive Impairment and Vitamin B12, Folate, and Homocysteine Status in Elderly Adults: A Retrospective Study. J. Alzheimer’s Dis. 2019, 70, 441–451. [Google Scholar] [CrossRef]
  60. Mendonça, N.; Granic, A.; Mathers, J.C.; Martin-Ruiz, C.; Wesnes, K.A.; Seal, C.J.; Jagger, C.; Hill, T.R. One-Carbon Metabolism Biomarkers and Cognitive Decline in the Very Old: The Newcastle 85+ Study. J. Am. Med. Dir. Assoc. 2017, 18, 806.e19–806.e27. [Google Scholar] [CrossRef]
  61. Zhou, X.; Wang, Q.; An, P.; Du, Y.; Zhao, J.; Song, A.; Huang, G. Relationship between Folate, Vitamin B12, Homocysteine, Transaminase and Mild Cognitive Impairment in China: A Case-Control Study. Int. J. Food Sci. Nutr. 2020, 71, 315–324. [Google Scholar] [CrossRef]
  62. Moore, E.M.; Ames, D.; Mander, A.G.; Carne, R.P.; Brodaty, H.; Woodward, M.C.; Boundy, K.; Ellis, K.A.; Bush, A.I.; Faux, N.G.; et al. Among Vitamin B12 Deficient Older People, High Folate Levels Are Associated with Worse Cognitive Function: Combined Data from Three Cohorts. J. Alzheimer’s Dis. 2014, 39, 661–668. [Google Scholar] [CrossRef]
  63. Senger, J.; Bruscato, N.M.; Werle, B.; Moriguchi, E.H.; Pattussi, M.P. Nutritional Status and Cognitive Impairment among the Very Old in a Community Sample from Southern Brazil. J. Nutr. Health Aging 2019, 23, 923–929. [Google Scholar] [CrossRef]
  64. Soh, Y.; Lee, D.H.; Won, C.W. Association between Vitamin B12 Levels and Cognitive Function in the Elderly Korean Population. Medicine 2020, 99, e21371. [Google Scholar] [CrossRef]
  65. Kim, S.H.; Park, Y.M.; Choi, B.Y.; Kim, M.K.; Roh, S.; Kim, K.; Yang, Y.J. Associations of Serum Levels of Vitamins A, C, and E with the Risk of Cognitive Impairment among Elderly Koreans. Nutr. Res. Pract. 2018, 12, 160–165. [Google Scholar] [CrossRef] [Green Version]
  66. Mangialasche, F.; Solomon, A.; Kåreholt, I.; Hooshmand, B.; Cecchetti, R.; Fratiglioni, L.; Soininen, H.; Laatikainen, T.; Mecocci, P.; Kivipelto, M. Serum Levels of Vitamin E Forms and Risk of Cognitive Impairment in a Finnish Cohort of Older Adults. Exp. Gerontol. 2013, 48, 1428–1435. [Google Scholar] [CrossRef] [PubMed]
  67. Yuan, L.; Liu, J.; Ma, W.; Dong, L.; Wang, W.; Che, R.; Xiao, R. Dietary Pattern and Antioxidants in Plasma and Erythrocyte in Patients with Mild Cognitive Impairment from China. Nutrition 2016, 32, 193–198. [Google Scholar] [CrossRef] [PubMed]
  68. Shahar, S.; Lee, L.K.; Rajab, N.; Lim, C.L.; Harun, N.A.; Noh, M.F.N.M.; Mian-Then, S.; Jamal, R. Association between Vitamin A, Vitamin E and Apolipoprotein E Status with Mild Cognitive Impairment among Elderly People in Low-Cost Residential Areas. Nutr. Neurosci. 2013, 16, 6–12. [Google Scholar] [CrossRef] [PubMed]
  69. Rietman, M.L.; Spijkerman, A.M.W.; Wong, A.; van Steeg, H.; Bürkle, A.; Moreno-Villanueva, M.; Sindlinger, T.; Franceschi, C.; Grubeck-Loebenstein, B.; Bernhardt, J.; et al. Antioxidants Linked with Physical, Cognitive and Psychological Frailty: Analysis of Candidate Biomarkers and Markers Derived from the MARK-AGE Study. Mech. Ageing Dev. 2019, 177, 135–143. [Google Scholar] [CrossRef] [Green Version]
  70. Rivan, N.F.M.; Shahar, S.; Rajab, N.F.; Singh, D.K.A.; Din, N.C.; Hazlina, M.; Hamid, T.A.T.A. Cognitive Frailty among Malaysian Older Adults: Baseline Findings from the LRGS TUA Cohort Study. Clin. Interv. Aging 2019, 14, 1343–1352. [Google Scholar] [CrossRef]
  71. Llewellyn, D.J. Serum Albumin Concentration and Cognitive Impairment. Curr. Alzheimer Res. 2010, 7, 91–96. [Google Scholar] [CrossRef]
  72. Supasitthumrong, T.; Tunvirachaisakul, C.; Aniwattanapong, D.; Tangwongchai, S.; Chuchuen, P.; Tawankanjanachot, I.; Snabboon, T.; Hemrungrojn, S.; Carvalho, A.F.; Maes, M. Peripheral Blood Biomarkers Coupled with the Apolipoprotein E4 Genotype Are Strongly Associated with Semantic and Episodic Memory Impairments in Elderly Subjects with Amnestic Mild Cognitive Impairment and Alzheimer’s Disease. J. Alzheimer’s Dis. 2019, 71, 797–811. [Google Scholar] [CrossRef]
  73. Wang, L.; Wang, F.; Liu, J.; Zhang, Q.; Lei, P. Inverse Relationship between Baseline Serum Albumin Levels and Risk of Mild Cognitive Impairment in Elderly: A Seven-Year Retrospective Cohort Study. Tohoku J. Exp. Med. 2018, 246, 51–57. [Google Scholar] [CrossRef] [Green Version]
  74. Lukaschek, K.; Von Schacky, C.; Kruse, J.; Ladwig, K.H. Cognitive Impairment Is Associated with a Low Omega-3 Index in the Elderly: Results from the KORA-Age Study. Dement. Geriatr. Cogn. Disord. 2016, 42, 236–245. [Google Scholar] [CrossRef] [Green Version]
  75. Yuan, L.; Zhen, J.; Ma, W.; Cai, C.; Huang, X.; Xiao, R. The Erythrocyte Fatty Acid Profile and Cognitive Function in Old Chinese Adults. Nutrients 2016, 8, 385. [Google Scholar] [CrossRef] [Green Version]
  76. Orsitto, G.; Fulvio, F.; Tria, D.; Turi, V.; Venezia, A.; Manca, C. Nutritional Status in Hospitalized Elderly Patients with Mild Cognitive Impairment. Clin. Nutr. 2009, 28, 100–102. [Google Scholar] [CrossRef]
  77. Shawky Khater, M.; Fawzy Abouelezz, N. Nutritional Status in Older Adults with Mild Cognitive Impairment Living in Elderly Homes in Cairo, Egypt. J. Nutr. Health Aging 2011, 15, 104–108. [Google Scholar] [CrossRef] [PubMed]
  78. Etgen, T.; Sander, D.; Bickel, H.; Sander, K.; Förstl, H. Vitamin D Deficiency, Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis. Dement. Geriatr. Cogn. Disord. 2012, 33, 297–305. [Google Scholar] [CrossRef] [PubMed]
  79. Yang, T.; Wang, H.; Xiong, Y.; Chen, C.; Duan, K.; Jia, J.; Ma, F. Vitamin D Supplementation Improves Cognitive Function through Reducing Oxidative Stress Regulated by Telomere Length in Older Adults with Mild Cognitive Impairment: A 12-Month Randomized Controlled Trial. J. Alzheimer’s Dis. 2020, 78, 1509–1518. [Google Scholar] [CrossRef]
  80. Muscogiuri, G.; Sorice, G.P.; Ajjan, R.; Mezza, T.; Pilz, S.; Prioletta, A.; Scragg, R.; Volpe, S.L.; Witham, M.D.; Giaccari, A. Can Vitamin D Deficiency Cause Diabetes and Cardiovascular Diseases? Present Evidence and Future Perspectives. Nutr. Metab. Cardiovasc. Dis. 2012, 22, 81–87. [Google Scholar] [CrossRef]
  81. Leritz, E.C.; McGlinchey, R.E.; Kellison, I.; Rudolph, J.L.; Milberg, W.P. Cardiovascular Disease Risk Factors and Cognition in the Elderly. Curr. Cardiovasc. Risk Rep. 2011, 5, 407–412. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  82. Garcion, E.; Wion-Barbot, N.; Montero-Menei, C.N.; Berger, F.; Wion, D. New Clues about Vitamin D Functions in the Nervous System. Trends Endocrinol. Metab. 2002, 13, 100–105. [Google Scholar] [CrossRef]
  83. Brown, J.; Bianco, J.I.; McGrath, J.J.; Eyles, D.W. 1,25-Dihydroxyvitamin D3 Induces Nerve Growth Factor, Promotes Neurite Outgrowth and Inhibits Mitosis in Embryonic Rat Hippocampal Neurons. Neurosci. Lett. 2003, 343, 139–143. [Google Scholar] [CrossRef]
  84. Masoumi, A.; Goldenson, B.; Ghirmai, S.; Avagyan, H.; Zaghi, J.; Abel, K.; Zheng, X.; Espinosa-Jeffrey, A.; Mahanian, M.; Liu, P.T.; et al. 1α, 25-Dihydroxyvitamin D 3 interacts with curcuminoids to stimulate amyloid-β clearance by macrophages of Alzheimer’s disease patients. J. Alzheimer’s Dis. 2009, 17, 703–717. [Google Scholar] [CrossRef] [PubMed]
  85. Ricardo, J.; Martel, F.; Borges, N.; Manuel, J.; Keating, E. Folates and Aging: Role in Mild Cognitive Impairment, Dementia and Depression. Ageing Res. Rev. 2015, 22, 9–19. [Google Scholar] [CrossRef]
  86. Zhang, X.; Bao, G.; Liu, D.; Yang, Y.; Li, X. The Association Between Folate and Alzheimer’ s Disease: A Systematic Review and Meta-Analysis. Front. Neurosci. 2021, 15, 661198. [Google Scholar] [CrossRef]
  87. Smith, A.D.; Refsum, H. Vitamin B-12 and Cognition in the Elderly 1–4. Am. J. Clin. Nutr. 2009, 89, 707–711. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  88. Zhang, C.; Luo, J.; Yuan, C.; Ding, D. Vitamin B12, B6, or Folate and Cognitive Function in Community-Dwelling Older Adults: A Systematic Review and Meta-Analysis. J. Alzheimer’s Dis. 2020, 77, 781–794. [Google Scholar] [CrossRef] [PubMed]
  89. Quadri, P.; Fragiacomo, C.; Pezzati, R.; Zanda, E.; Forloni, G.; Tettamanti, M.; Lucca, U. Homocysteine, Folate, and Vitamin B-12 in Mild Cognitive Impairment, Alzheimer Disease, and Vascular Dementia. Am. J. Clin. Nutr. 2004, 80, 114–122. [Google Scholar] [CrossRef] [PubMed]
  90. Beydoun, M.A.; Beydoun, H.A.; Gamaldo, A.A.; Teel, A.; Zonderman, A.B.; Wang, Y. Epidemiologic Studies of Modifiable Factors Associated with Cognition and Dementia: Systematic Review and Meta-Analysis. BMC Public Health 2014, 14, 643. [Google Scholar] [CrossRef] [PubMed]
  91. Morris, M.S. The Role of B Vitamins in Preventing and Treating Cognitive Impairment and Decline. Adv. Nutr. 2012, 3, 801–812. [Google Scholar] [CrossRef] [Green Version]
  92. Mischoulon, D.; Raab, M.F. The Role of Folate in Depression and Dementia. J. Clin. Psychiatry 2007, 68, 28–33. [Google Scholar]
  93. Ho, P.I.; Collins, S.C.; Dhitavat, S.; Ortiz, D.; Ashline, D.; Rogers, E.; Shea, T.B. Homocysteine Potentiates β-Amyloid Neurotoxicity: Role of Oxidative Stress. J. Neurochem. 2001, 78, 249–253. [Google Scholar] [CrossRef] [PubMed]
  94. Obeid, R.; Herrmann, W. Mechanisms of Homocysteine Neurotoxicity in Neurodegenerative Diseases with Special Reference to Dementia. FEBS Lett. 2006, 580, 2994–3005. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  95. Marlatt, M.; Lucassen, P.; Perry, G.; Smith, M.; Zhu, X. Alzheimer’s Disease: Cerebrovascular Dysfunction, Oxidative Stress, and Advanced Clinical Therapies. J. Alzheimers. Dis. 2008, 15, 199–210. [Google Scholar] [CrossRef] [Green Version]
  96. Cao, L.; Tan, L.; Wang, H.F.; Jiang, T.; Zhu, X.C.; Lu, H.; Tan, M.S.; Yu, J.T. Dietary Patterns and Risk of Dementia: A Systematic Review and Meta-Analysis of Cohort Studies. Mol. Neurobiol. 2016, 53, 6144–6154. [Google Scholar] [CrossRef] [PubMed]
  97. Ricciarelli, R.; Argellati, F.; Pronzato, M.A.; Domenicotti, C. Vitamin E and Neurodegenerative Diseases. Mol. Aspects Med. 2007, 28, 591–606. [Google Scholar] [CrossRef]
  98. Reiter, E.; Jiang, Q.; Christen, S. Anti-Inflammatory Properties of α- and γ-Tocopherol. Mol. Aspects Med. 2007, 28, 668–691. [Google Scholar] [CrossRef] [Green Version]
  99. Wołoszynowska-Fraser, M.U.; Kouchmeshky, A.; McCaffery, P. Vitamin A and Retinoic Acid in Cognition and Cognitive Disease. Annu. Rev. Nutr. 2020, 40, 247–272. [Google Scholar] [CrossRef]
  100. Sodhi, R.K.; Singh, N. All-Trans Retinoic Acid Rescues Memory Deficits and Neuropathological Changes in Mouse Model of Streptozotocin-Induced Dementia of Alzheimer’s Type. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2013, 40, 38–46. [Google Scholar] [CrossRef] [PubMed]
  101. Fragoso, Y.D.; Stoney, P.N.; McCaffery, P.J. The Evidence for a Beneficial Role of Vitamin A in Multiple Sclerosis. CNS Drugs 2014, 28, 291–299. [Google Scholar] [CrossRef] [PubMed]
  102. Ono, K.; Yamada, M. Vitamin A and Alzheimer’s Disease. Geriatr. Gerontol. Int. 2012, 12, 180–188. [Google Scholar] [CrossRef]
  103. Brooke, J.; Ojo, O. Enteral Nutrition in Dementia: A Systematic Review. Nutrients 2015, 7, 2456–2468. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  104. Faxén-Irving, G.; Basun, H.; Cederholm, T. Nutritional and Cognitive Relationships and Long-Term Mortality in Patients with Various Dementia Disorders. Age Ageing 2005, 34, 136–141. [Google Scholar] [CrossRef] [Green Version]
  105. Covinsky, K.E.; Covinsky, M.H.; Palmer, R.M.; Sehgal, A.R. Serum Albumin Concentration and Clinical Assessments of Nutritional Status in Hospitalized Older People: Different Sides of Different Coins? J. Am. Geriatr. Soc. 2002, 50, 631–637. [Google Scholar] [CrossRef]
  106. Karakis, I.; Pase, M.; Beiser, A.; Booth, S.; Jacques, P.; Rogers, G.; DeCarli, C.; Vasan, R.; Wang, T.; Himali, J.; et al. Association of Serum Vitamin D with the Risk of Incident Dementia and Subclinical Indices of Brain Aging: The Framingham Heart Study. J. Alzheimers Dis. 2016, 51, 451–461. [Google Scholar] [CrossRef] [Green Version]
  107. Ohlsson, O.; Henningsen, N.C.; Malmquist, I. Blood Pressure, Heart Rate and Plasma Albumin in Relatives of Hypertensive Patients. Acta Med. Scand. 1981, 209, 445–450. [Google Scholar] [CrossRef]
  108. Mao, P. Oxidative Stress and Its Clinical Applications in Dementia. J. Neurodegener. Dis. 2013, 2013, 319898. [Google Scholar] [CrossRef] [Green Version]
  109. Guo, J.; Jono, H.; Kugimiya, T.; Saito, S.; Maruyama, T.; Misumi, Y.; Hoshii, Y.; Su, Y.; Shono, M.; Ueda, M.; et al. Antioxidative Effect of Albumin on Amyloid Fibril Formation in Transthyretin-Related Amyloidosis. Amyloid 2011, 18 (Suppl. 1), 12–13. [Google Scholar] [CrossRef]
  110. Cole, G.M.; Ma, Q.L.; Frautschy, S.A. Omega-3 Fatty Acids and Dementia. Prostaglandins Leukot. Essent. Fat. Acids 2009, 81, 213–221. [Google Scholar] [CrossRef] [Green Version]
  111. Fotuhi, M.; Mohassel, P.; Yaffe, K. Fish Consumption, Long-Chain Omega-3 Fatty Acids and Risk of Cognitive Decline or Alzheimer Disease: A Complex Association. Nat. Clin. Pract. Neurol. 2009, 5, 140–152. [Google Scholar] [CrossRef]
  112. Janssen, C.I.F.; Kiliaan, A.J. Long-Chain Polyunsaturated Fatty Acids (LCPUFA) from Genesis to Senescence: The Influence of LCPUFA on Neural Development, Aging, and Neurodegeneration. Prog. Lipid Res. 2014, 53, 1–17. [Google Scholar] [CrossRef]
  113. Lukiw, W.J.; Bazan, N.G. Docosahexaenoic Acid and the Aging Brain. J. Nutr. 2008, 138, 2510–2514. [Google Scholar] [CrossRef] [Green Version]
  114. Huang, T.L. Omega-3 Fatty Acids, Cognitive Decline, and Alzheimer’s Disease: A Critical Review and Evaluation of the Literature. J. Alzheimer’s Dis. 2010, 21, 673–690. [Google Scholar] [CrossRef]
  115. Lorenzo-López, L.; Maseda, A.; De Labra, C.; Regueiro-Folgueira, L.; Rodríguez-Villamil, J.L.; Millán-Calenti, J.C. Nutritional Determinants of Frailty in Older Adults: A Systematic Review. BMC Geriatr. 2017, 17, 108. [Google Scholar] [CrossRef] [Green Version]
  116. Zhou, J.; Huang, P.; Liu, P.; Hao, Q.; Chen, S.; Dong, B.; Wang, J. Maturitas Association of Vitamin D Deficiency and Frailty: A Systematic Review and Meta-Analysis. Maturitas 2016, 94, 70–76. [Google Scholar] [CrossRef]
  117. Guilbaud, A.; Puisieux, F.; Dauchet, L. Circulating Biomarkers Characterizing Physical Frailty: CRP, Hemoglobin, Albumin, 25OHD and Free Testosterone as Best Biomarkers. Results of a meta-analysis. Exp. Gerontol. 2021, 139, 111014. [Google Scholar] [CrossRef]
  118. Houston, D.K.; Neiberg, R.H.; Tooze, J.A.; Hausman, D.B.; Johnson, M.A.; Cauley, J.A.; Bauer, D.C.; Shea, M.K.; Schwartz, G.G.; Williamson, J.D.; et al. Low 25-Hydroxyvitamin D Predicts the Onset of Mobility Limitation and Disability in Community-Dwelling Older Adults: The Health ABC Study. J. Gerontol.-Ser. A Biol. Sci. Med. Sci. 2013, 68, 181–187. [Google Scholar] [CrossRef] [Green Version]
  119. Ceglia, L. Vitamin D and Skeletal Muscle Tissue and Function. Mol. Aspects Med. 2008, 29, 407–414. [Google Scholar] [CrossRef]
  120. Shardell, M.; Hicks, G.E.; Miller, R.R.; Kritchevsky, S.; Andersen, D.; Bandinelli, S.; Cherubini, A.; Ferrucci, L. Association of Low Vitamin D Levels with the Frailty Syndrome in Men and Women. J. Gerontol.-Ser. A Biol. Sci. Med. Sci. 2009, 64, 69–75. [Google Scholar] [CrossRef] [Green Version]
  121. Hubbard, R.E.; O’Mahony, M.S.; Savva, G.M.; Calver, B.L.; Woodhouse, K.W. Inflammation and Frailty Measures in Older People. J. Cell. Mol. Med. 2009, 13, 3103–3109. [Google Scholar] [CrossRef]
  122. Ben-Dor, A.; Steiner, M.; Gheber, L.; Danilenko, M.; Dubi, N.; Linnewiel, K.; Zick, A.; Sharoni, Y.; Levy, J. Carotenoids Activate the Antioxidant Response Element Transcription System. Mol. Cancer Ther. 2005, 4, 177–186. [Google Scholar] [CrossRef] [PubMed]
  123. Sugiura, M.; Nakamura, M.; Ogawa, K.; Ikoma, Y.; Yano, M. High Serum Carotenoids Associated with Lower Risk for Bone Loss and Osteoporosis in Post-Menopausal Japanese Female Subjects: Prospective Cohort Study. PLoS ONE 2012, 7, e52643. [Google Scholar] [CrossRef] [PubMed]
  124. Hamerman, D. Toward an Understanding of Frailty. Ann. Intern. Med. 1999, 130, 945–950. [Google Scholar] [CrossRef]
  125. Chojkier, M. Inhibition of Albumin Synthesis in Chronic Diseases: Molecular Mechanisms. J. Clin. Gastroenterol. 2005, 39, 143–146. [Google Scholar] [CrossRef]
  126. Wu, I.C.; Shiesh, S.C.; Kuo, P.H.; Lin, X.Z. High Oxidative Stress Is Correlated with Frailty in Elderly Chinese. J. Am. Geriatr. Soc. 2009, 57, 1666–1671. [Google Scholar] [CrossRef] [PubMed]
  127. Ponvel, P.; Shahar, S.; Kaur, D.; Singh, A.; Fitri, A.; Ludin, M. Multidomain Intervention for Reversal of Cognitive Frailty, Towards a Personalized Approach (AGELESS Trial): Study Design. J. Alzheimer’s Dis. 2021, 82, 673–687. [Google Scholar] [CrossRef]
Figure 1. PRISMA flow diagram for the selection of related articles.
Figure 1. PRISMA flow diagram for the selection of related articles.
Ijerph 19 15722 g001
Figure 2. Summary of findings on the association between micronutrient malnutrition and mild cognitive impairment, frailty, and cognitive frailty involved in the elderly.
Figure 2. Summary of findings on the association between micronutrient malnutrition and mild cognitive impairment, frailty, and cognitive frailty involved in the elderly.
Ijerph 19 15722 g002
Table 1. Lists of keywords and synonyms generated as search terms.
Table 1. Lists of keywords and synonyms generated as search terms.
Blood Micronutrient ProfilesCognitive FrailtyOlder Adult
AlbuminCognitive impairmentsAging population
HomocysteineCognitive dysfunctionOlder population
Amino acidsMild cognitive impairmentsAging
Fatty acidsPhysical frailtyElderly
MineralsFrailty syndrome
VitaminsDebility
Antioxidants
Table 2. List of search strings.
Table 2. List of search strings.
Search strings“Blood micronutrient profiles” OR “Albumin” OR “Homocysteine” OR “Amino Acids” OR “Fatty Acids” OR “Minerals” OR “Vitamins” OR “Antioxidants” AND “Cognitive frailty” OR “Cognitive impairment” OR “Cognitive dysfunction” OR “Mild cognitive impairments” OR “Physical frailty” OR “Frailty syndrome” OR “Debility” AND “Older adults” OR “Aging population” OR “Older population” OR “Ageing” OR “Elderly”
Table 4. Summary of studies evaluating the association between B vitamins with mild cognitive impairment, frailty, and cognitive frailty involved in the elderly.
Table 4. Summary of studies evaluating the association between B vitamins with mild cognitive impairment, frailty, and cognitive frailty involved in the elderly.
Author, Year, CountryStudy DesignParticipant CharacteristicsMicronutrient in Blood Profiles’ Outcomes and Methods of MeasurementFindings
Castillo-Lancellotti et al., 2014 [57]
Chile
Cross-sectional studySubjects: 1051 older adults who participated in the National Health Survey 2009–2010
Age: 65 years old and older
The blood samples were obtained from fasting individuals and were processed within 4 h of venepuncture. Serum folate and vitamin B12 levels were determined by competitive immunoassay using direct chemiluminescence.Low serum folate levels significantly increased the risk of cognitive impairment (p = 0.026).
Kim et al., 2013 [58]
South Korea
Cross-sectional studySubjects: 321 older adults in the Songpa district
Age: 60 years old and older
A fasting blood sample was drawn from each subject and the plasma samples were stored at −80 °C until analysis. Plasma folate and vitamin B12 were analyzed using a radioimmunoassay kit and a gamma counter. Plasma homocysteine was measured using HPLC with a fluorescence detector.Plasma folate level was positively associated with the cognitive function test scores in the mild cognitive impairment (MCI) group (β = 0.840, p = 0.040).
Moore et al., 2014 [62]
Australia
Cross-sectional studySubjects: 1354 older adults from the Prospective Research in Memory (PRIME) clinics study and the Australian Imaging, Biomarkers and Lifestyle (AIBL) study and from patients attending for assessment or management of memory problems
Age: 60 years old and older
Blood samples
were taken within six months of cognitive testing. Serum vitamin B12 and red cell folate (RCF) levels were measured using the ADVIA Centaur chemiluminescent
microparticle immunoassay, Tosoh
immunoassay analyzer AIA600,
the Roche Cobas 8000 electrochemiluminescence
immunoassay, and Siemens Healthcare Diagnostic Immulite 2000 immunoassay.
Participants with low serum vitamin B12 (<250 pmol/L) and high red cell folate (>1594 nmol/L) levels were more likely to have impaired cognitive performance (adjusted odds ratio (AOR) = 3.45, 95% CI: 1.60–7.43, p = 0.002; and AOR = 1.74, 95% CI: 1.03–2.95, p = 0.04, respectively) as compared to participants with biochemical measurements that were within the normal range.
Rosa et al., 2019 [39]
Brazil
Cross-sectional studySubjects: 165 older adults
Age: 80 years old and older
All blood samples were collected after a 12 h fast, and the serum was stored at −20 °C until analysis. Serum vitamin B12 was measured using the chemiluminescent microparticle
immunoassay on the BitLab system.
A high concentration of B12 levels (≥496 pg mL−1) indicated a risk factor for cognitive decline (prevalence ratio = 1.90, 95% CI: 1.08–3.36).
Senger et al., 2019 [63]
Brazil
Cross-sectional studySubjects: 153 older adults
Age: 80 years and older
Serum albumin levels were determined with the calorimetric method. Serum vitamin B12 was
measured with the immunoassay technique.
Low vitamin B12 concentration positively associated with cognitive impairment (AOR = 5.37, 95% CI: 1.44–19.97, p = 0.012).
Soh et al., 2020 [64]
Korea
Cross-sectional studySubjects: 2991 older adults (1416 males and 1575 females)
Age: 70–84 years old
Serum samples were collected, and vitamin B12 was measured with an Architect vitamin kit.The association between the B12 group and cognitive function was not statistically significant (p > 0.05).
Dokuzlar et al., 2017 [43]
Turkey
Cross-sectional studySubjects: 335 patients who attended geriatric polyclinics (88
frail, 156 prefrail, and controls)
Age: 60 years old and older
Serum vitamin B12 was measured using a diagnostic modular system autoanalyzer.No association between vitamin B12 level and frailty (p > 0.05).
Mendonça et al., 2017 [60]
United Kingdom
Prospective studySubjects: 765 community-dwelling and institutionalized older adults
Age: 85 years old and older
Blood was drawn between 7:00 and 10:30 AM after an overnight fast, and red blood cells (RBC) folate and plasma vitamin B12 were quantified by chemiluminescence. Total homocysteine (tHcy) was measured with an Abbot Imx immunoassay. Data were collected at baseline; 18 months, 36 months, and 60 months.RBC folate and plasma tHcy were significantly associated with better global cognition at baseline (β = +1.02, SE = 0.43, p = 0.02; and β = −1.05, SE = 0.46, p = 0.02, respectively).
Zhou et al., 2020 [61]
China
Case-control studySubjects: 118 subjects with MCI and 118 subjects without MCI
Age: 60 years old and older
Blood samples were collected, processed, and stored at −80 °C until analysis. The concentrations of serum folate and vitamin B12 were determined using the Abbott Architect-i2000SR automated chemiluminescence immunoassay system. The concentrations of plasma Hcy were determined by HPLC.Increased Hcy levels and lower folate levels were independently associated with the risk of MCI (OR = 3.93, 95% CI: 1.54–10.07, p = 0.004; and OR = 0.24, 95% CI: 0.11–0.52, p = 0.000, respectively).
Baroni et al., 2019 [59]
Italy
RetrospectiveSubjects: 569 older adults
attended the Centre for Diagnosis and Treatment of Cognitive Disorders (226 males and 343 females)
Age: 60–96 years old
A 6-year observational, retrospective study was conducted by collecting routine blood analyses. Serum vitamin B12 and folate were measured by Immulite 2000 immunoassay system and plasma homocysteine by Cobas c702 chemistry analyzer.Higher folate concentrations were significantly correlated with better cognitive performances (beta = 0.144, p = 0.001).
Table 5. Summary of studies evaluating the association between antioxidants with mild cognitive impairment, frailty, and cognitive frailty involved in the elderly.
Table 5. Summary of studies evaluating the association between antioxidants with mild cognitive impairment, frailty, and cognitive frailty involved in the elderly.
Author, Year, CountryStudy DesignParticipant CharacteristicsMicronutrient in Blood Profiles’ Outcomes and Methods of MeasurementFindings
Kim et al., 2018 [65]
Korea
Cross-sectional studySubjects: 230 older adults from Yangpyeong cohort
Age: 60–79 years old
Participants provided blood specimens after overnight fasting. Serum levels of vitamins A, C, and E (alpha tocopherol, beta tocopherol, and gamma tocopherol) were measured by high performance liquid chromatography (HPLC).There was no significant association between the risk of cognitive impairment and serum levels of vitamin A and vitamin C (p > 0.05). β-gamma tocopherol levels were inversely associated with cognitive impairment (OR = 0.37, 95% CI: 0.14–0.98, p for trend = 0.051).
Shahar et al., 2013 [70]
Malaysia
Cross-sectional studySubjects: 333 older adults
Age: 60 years old and older
Fasting venous blood was obtained, and the serum was stored at −40 °C until analysis. Vitamin A (serum retinol) and vitamin E (alpha tocopherol) statuses were determined in subsamples using HPLC.Vitamin A deficiency was associated with an increased risk of MCI (AOR = 3.253, 95% CI: 0.972–10.886, p < 0.05).
O’Halloran et al., 2020 [47]
Ireland
Cross-sectional studySubjects: 4068 participants
Age: 50 years old and older
Non-fasting whole blood samples were collected between 09:30 AM and 16:30 PM by venipuncture, and the plasma was separated from the blood samples within 48 h of collection and archived at −80 °C until assayed. Lutein and zeaxanthin were measured by
the reverse-phase high performance liquid chromatography method.
All 3 measures of frailty were associated with lower levels of lutein (RRR = 0.43–0.63) and zeaxanthin (RRR = 0.49–0.63).
Rietman et al., 2019 [69]
Europe
Cross-sectional studySubjects: 2220 participants from Randomly Recruited Age-Stratified
Individuals from the General Population (RASIG) study population
Age: 35–74 years old
Analysis by the Universitaet Hohenheim.Levels of β-cryptoxanthin and zeaxanthin were inversely associated with the risk of being cognitively frail (OR = 0.742, 95% CI: 0.604–0.911, p = 0.0043; and OR = 0.752, 95% CI: 0.588–0.960, p = 0.0225, respectively).
Mangialasche et al., 2013 [66]
Finland
Prospective studySubjects: 140 non-cognitively impaired older adult subjects derived from the Cardiovascular Risk Factors, Aging, and Dementia (CAIDE) study
Age: 65–79 years old
Blood samples were taken after a minimum of 2 h fasting, and all serum samples were stored at −70 °C until analysis. The mean duration of follow-up was 8.2 years. Serum tocopherols, tocotrienols, αTQ, and 5-NO2-γ-tocopherol were measured with
reverse-phase HPLC.
Elevated levels of tocopherol and tocotrienol forms were significantly associated with reduced risk of cognitive
impairment in older adults (OR = 0.33, 95% CI: 0.11–0.97 for γ-tocopherol; OR = 0.21, 95% CI: 0.06–0.71 for β-tocotrienol; and OR = 0.33, 95% CI: 0.10–1.06 for γ-tocotrienol).
Yuan et al., 2016 [67]
China
Case-control studySubjects: 138 MCI patients and 138 age- and sex-matched healthy controls
Age: 55–75 years old
Fasting venous blood samples were collected, processed, and stored at −80 °C until analysis. Plasma retinol and α-tocopherol
were determined by using HPLC with UV detection.
Lower α-tocopherol was detected in the MCI patients compared to the control group
(p < 0.05).
Table 6. Summary of studies evaluating the association between protein with mild cognitive impairment, frailty, and cognitive frailty involved in the elderly.
Table 6. Summary of studies evaluating the association between protein with mild cognitive impairment, frailty, and cognitive frailty involved in the elderly.
Author, Year, CountryStudy DesignParticipant CharacteristicsMicronutrient in Blood Profiles’ Outcomes and Methods of MeasurementFindings
Llewellyn et al., 2009 [71]
United Kingdom
Cross-sectional studySubjects: 1752 older adults (699 males and 1053 females) from the Health Survey for England 2000
Age: 65 years old and older
Non-fasting blood samples were collected, and serum albumin was measured
using the DAX system.
Low serum albumin was independently associated with increased odds of cognitive impairment in the elderly population (OR = 2.5, 95% CI: 1.3–5.1, p for linear trend = 0.002).
Supasitthumrong et al., 2019 [72]
Thailand
Cross-sectional studySubjects: 182 older adults (60 with amnestic mild cognitive impairment (aMCI), 60 with Alzheimer’s disease (AD), and 62 normal controls (NC).
Age: 55–90 years old
Fasting blood was collected
between 8.00 and 8.30 AM, and serum albumin was measured using Architect C8000.
Serum albumin significantly affected cognitive functions (B = 0.148, SE = 0.061, p = 0.017), including episodic and semantic memory among elderly with MCI.
Dokuzlar et al., 2017 [43]
Turkey
Cross-sectional studySubjects: 335 patients who attended geriatric polyclinics (88
frail, 156 prefrail, and controls)
Age: 60 years old and older
Serum albumin was measured using a diagnostic modular system autoanalyzer.Level of albumin decreased as severity of frailty increased (p < 0.05).
Wang et al., 2018 [73]
China
Retrospective studySubjects: 1800 older adults
Age: 60 years old and older
A 7-year retrospective cohort study was conducted by collecting data from medical records including serum levels of albumin. The method for measurement of serum albumin was not stated.Low serum albumin levels
at baseline (<40.5 g/L) were associated with the increased risk of MCI (HR = 2.18, 95% CI: 1.67–2.82).
Table 7. Summary of studies evaluating the association between lipids with mild cognitive impairment, frailty, and cognitive frailty involved in the elderly.
Table 7. Summary of studies evaluating the association between lipids with mild cognitive impairment, frailty, and cognitive frailty involved in the elderly.
Author, Year, CountryStudy DesignParticipant CharacteristicsMicronutrient in Blood Profiles’ Outcomes and Methods of MeasurementFindings
Lukaschek et al., 2016 [74]
Germany
Cross-sectional studySubjects: 720 older adults from
(Cooperative Health Research in the Region of Augsburg) KORA-Age study
Age: 68–92 years old
Erythrocyte fatty acid composition was measured using gas chromatography.Low omega-3 index levels were significantly associated with cognitive impairment (OR = 1.77, 95% CI: 1.14–2.76, p = 0.01).
Chhetri et al., 2018 [34]
France
Cross-sectional studySubjects: 1680 older adults from the Multi-domain Alzheimer Disease
Preventive Trial (MAPT)
Age: 70 years old and older
Blood samples were taken during enrollment.
Erythrocyte membrane fatty acids were measured using gas chromatography.
Low
n−3PUFA showed higher likelihood of physical limitation (OR = 1.55, 95% CI: 1.12 to 2.15,
p = 0.009).
Yuan et al., 2016 [75]
China
Case-control studySubjects: 60 MCI subjects and 60 age- and gender-matched control adults
Age: 55 years old and older
Fasting venous blood samples were collected between 8:00 and 9:00 AM from each subject. A fatty acid analysis was performed using gas chromatography (GC).Lower erythrocyte unsaturated fatty acid and higher saturated
fatty acid proportions might predict cognitive function decline in elderly Chinese adults. The percentage of erythrocyte DHA was positively correlated with the total MoCA score (r = 0.356, p < 0.05), while 12:0 fatty acid was inversely associated
with the total MoCA score
(r = 0.450, p < 0.05).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Mustafa Khalid, N.; Haron, H.; Shahar, S.; Fenech, M. Current Evidence on the Association of Micronutrient Malnutrition with Mild Cognitive Impairment, Frailty, and Cognitive Frailty among Older Adults: A Scoping Review. Int. J. Environ. Res. Public Health 2022, 19, 15722. https://doi.org/10.3390/ijerph192315722

AMA Style

Mustafa Khalid N, Haron H, Shahar S, Fenech M. Current Evidence on the Association of Micronutrient Malnutrition with Mild Cognitive Impairment, Frailty, and Cognitive Frailty among Older Adults: A Scoping Review. International Journal of Environmental Research and Public Health. 2022; 19(23):15722. https://doi.org/10.3390/ijerph192315722

Chicago/Turabian Style

Mustafa Khalid, Norhayati, Hasnah Haron, Suzana Shahar, and Michael Fenech. 2022. "Current Evidence on the Association of Micronutrient Malnutrition with Mild Cognitive Impairment, Frailty, and Cognitive Frailty among Older Adults: A Scoping Review" International Journal of Environmental Research and Public Health 19, no. 23: 15722. https://doi.org/10.3390/ijerph192315722

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop